

# Reverse Physician-AI Relationship: Full-process Clinical Diagnosis Driven by a Large Language Model

**Shicheng Xu<sup>1,2,†</sup>, Xin Huang<sup>3,†</sup>, Zihao Wei<sup>1,2,†</sup>, Liang Pang<sup>1,\*</sup>, Huawei Shen<sup>1</sup>, Xueqi Cheng<sup>1</sup>**

<sup>1</sup>State Key Laboratory of AI Safety, Institute of Computing Technology, CAS

<sup>2</sup>University of Chinese Academy of Sciences <sup>3</sup>Peking University Third Hospital

{xushicheng21s,weizihao, pangliang,shenhuawei,cxq}@ict.ac.cn hay221@163.com

## Abstract

Full-process clinical diagnosis in the real world encompasses the entire diagnostic workflow that begins with only an ambiguous chief complaint. While artificial intelligence (AI), particularly large language models (LLMs), is transforming clinical diagnosis, its role remains largely as an assistant to physicians. This AI-assisted working pattern makes AI can only answer specific medical questions at certain parts within the diagnostic process, but lack the ability to drive the entire diagnostic process starting from an ambiguous complaint, which still relies heavily on human physicians. This gap limits AI's ability to fully reduce physicians' workload and enhance diagnostic efficiency. To address this, we propose a paradigm shift that reverses the relationship between physicians and AI: repositioning AI as the primary director, with physicians serving as its assistants. So we present DxDirector-7B, an LLM endowed with advanced deep thinking capabilities akin to human "slow thinking," enabling it to autonomously drive the full-process diagnosis with minimal physician involvement. Furthermore, DxDirector-7B establishes a robust accountability framework for misdiagnoses, delineating responsibility between AI and human physicians. In evaluations across rare, complex, and real-world cases under full-process diagnosis setting, DxDirector-7B not only achieves significant superior diagnostic accuracy but also substantially reduces physician workload than state-of-the-art medical LLMs, such as MedFound-176B, as well as general-purpose LLMs such as GPT-4o and DeepSeek-V3-671B. Fine-grained analyses across multiple clinical departments and tasks validate its efficacy, with expert evaluations indicating its potential to serve as a viable substitute for medical specialists. These findings mark a new era where AI, traditionally a physicians' assistant, now effectively drives the entire diagnostic process to drastically reduce physicians' workload, indicating an efficient and accurate diagnostic solution.

## 1 Introduction

Full-process clinical diagnosis encompasses the entire diagnostic workflow connected with clinical decision making [2], beginning with a patient's vague chief complaint. Physicians must iteratively make differential diagnoses, design and interpret a series of appropriate diagnostic tests, and progressively refine their understanding of the patient's clinical information before reaching a definitive diagnosis [3, 28, 32]. This complex process demands not only extensive medical knowledge and advanced reasoning skills [43] but also imposes a substantial workload on physicians. Despite rigorous professional training, the misdiagnosis rate in clinical practice remains close to 20% [12, 22]. The growing patient demand continues to outpace the diagnostic capacity of physicians, underscoring the urgent need for more efficient and scalable diagnostic solutions [40, 26].

\*Corresponding Author † Equal Contributions.

Recent advances in large language models (LLMs), a rapidly evolving artificial intelligence technology, have demonstrated remarkable capabilities in language comprehension and generation. This progress has spurred growing interest in their potential applications in clinical diagnosis. Emerging studies suggest that LLMs exhibit promising diagnostic performance [9, 25, 27, 17], prompting the development of medical-specialized LLMs [33, 34, 47, 22, 7, 24, 30]. However, the role of LLMs in real-world diagnosis are limited as only assistants for physicians. This limitation arises primarily because current LLMs excel in diagnosing cases with comprehensive clinical data—such as symptoms, medical history, and diagnostic test results, or clear instructions [22, 34, 7]—whereas real-world full-process clinical diagnosis often begins with only a patient’s vague chief complaint [3, 11, 32] (Fig. 2 (a) and (b)). This makes LLMs can only provide assistance in making final diagnosis or answering specific medical questions at certain parts within the diagnostic process, while much more work of the diagnostic process still highly relies on human physicians, such as clinical reasoning, condition assessment, and designing diagnostic tests to progressively enrich the clinical information.

To address this challenge, we propose a paradigm shift in the role of LLMs in clinical diagnosis. Unlike existing LLMs, which function solely as assistants to physicians, our approach redefines this relationship by positioning the LLM as the primary director of the diagnostic process, with physicians serving as its assistants (Fig. 1). As described in the new era of Fig. 1, LLM drives the full-process clinical diagnosis. At the beginning, LLM can only access the patient’s vague chief complaint, and it gradually clarifies the patient’s condition, designs appropriate diagnostic tests, infers complex medical knowledge and clinical phenomena, and finally makes the diagnosis. During this process, LLM can dynamically request assistance from physicians only when it faces the clinical operations that the computer program-based LLM cannot complete, such as symptom observation, laboratory testing, physical examination, and so on. Physicians are LLM’s assistants to finish its requests and input the results back to it. LLM continues the subsequent diagnosis. The pattern of LLM requesting assistance adheres to the principle of minimizing physicians’ involvement, thereby reducing the workload and requirement for medical expertise of physicians as much as possible.

Building on this design, we introduce DxDirector-7B, an LLM with advanced deep thinking capabilities (like human “slow thinking”), capable of autonomously driving the full-process clinical diagnosis starting from a vague chief complaint. DxDirector-7B progressively executes the entire clinic diagnosis step-by-step, it performs deep thinking to determine the optimal strategy at each step and seeks assistance from human physicians only at necessary steps with the principle of minimizing physicians’ involvement. It dynamically assesses whether sufficient clinical information has been gathered to establish a final diagnosis or whether further diagnostic steps are required. The final diagnostic output includes a clear and comprehensive summary of the entire diagnosis process, with each fine-grained medical knowledge attached by authoritative medical literature, thereby enhancing the verifiability of AI-generated diagnoses. Furthermore, this structured output establishes a robust accountability framework between physicians and the LLM, ensuring traceability in misdiagnosis.

We evaluate DxDirector-7B in the full-process clinical diagnosis setting using both real-world scenarios and four authoritative publicly available datasets. The evaluation datasets comprise 26,018 cases, including rare, complex, and diagnostically challenging cases reported in NEJM Clinicopathologic Cases [4], cases from the U.S. Medical Licensing Examination [16], and cases of real-world inpatients from officially certified Grade 3A hospitals in China. To ensure a comprehensive assessment, we conduct fine-grained evaluations across 19 clinical departments (e.g., neurosurgery, oncology, endocrinology) and 12 clinical tasks (e.g., diagnosis, differential diagnosis, treatment). Experimental results indicate that in terms of full-process clinical diagnostic accuracy, our DxDirector-7B significantly surpasses the medical adapted LLMs with dozens of times more parameters, such as MedFound-176B [22] and OpenbioLLM-70B. It also significantly surpasses the current strongest commercial general-purpose LLMs with nearly 100 times more parameters, such as GPT-4o, o1-preview, o3-mini, and Deepseek-V3-671B. Notably, DxDirector-7B achieves this superior performance while requiring significantly lower physician involvement than all comparison LLMs. These findings show that DxDirector-7B achieves the best accuracy with significantly lower computational and training costs, requiring the lowest human physicians’ efforts in the entire diagnosis process. Evaluations with the participation of medical specialists show that in real-world full-process diagnostic scenarios, the diagnoses generated by our DxDirector-7B achieve substitution for medical specialists in 60% to 75% of cases in many departments such as pulmonology and gastroenterology. Further analysis highlights its ability to provide a fine-grained verification framework for AI-generated diagnoses, establishing a robust accountability mechanism between physicians and AI in misdiagnosis.




Figure 1: Workflow of full-process diagnosis in past, now and the new era. The inner circle represents the directorship (deciding the specific clinical problems) of multi-step dynamic clinical diagnosis, and the outer circle represents the specific execution of the corresponding steps (solving the clinical problems). In the past, all work is done by human physicians. Now, AI, especially LLM, has reduced physicians’ workload to a certain extent, but AI can only serve as an assistant to answer questions designed by physicians at specific steps, and lacks the ability to drive the full diagnosis process starting from the chief complaint, which still relies heavily on physicians. Our DxDirector-7B, marks a new era that AI can drive the full-process diagnosis, only needs physicians as assistants to conduct some clinical operations at necessary steps, reducing the workload of physicians as much as possible.

This paper marks a new era where AI, traditionally a physicians’ assistant, now leads the entire diagnostic process with minimal physician involvement. It advances effective AI deployment in full-process clinical workflows of the real world, reducing the workload of physicians to the greatest extent possible and indicating the efficient, accurate and scalable diagnostic solution.

## 2 Results

In this section, we first give an overview of our DxDirector-7B and its training method. Then, we present the comprehensive experimental results about comparing DxDirector-7B with the most advanced medically adapted LLMs and commercial general-purpose LLMs.

### 2.1 Overview and Training Method of DxDirector-7B

#### 2.1.1 Overview

The overall workflow of our DxDirector-7B is shown in Fig. 2 (c) and the practical case of DxDirector-7B is illustrated in Fig. 3. As shown in Fig. 2 (a) and (b), current LLMs typically rely on complete clinical information for diagnosis, a scenario that rarely aligns with real-world clinical practice, where initial information often consists solely of a vague chief complaint. This means human physicians still need to pay much workload between getting chief complaint and making final diagnosis, and LLMs are just assistants in certain parts of this entire complex process. To address this disparity, we introduce DxDirector-7B, an advanced LLM with powerful deep thinking ability to drive the full-process clinical diagnosis starting with only a patient’s vague chief complaint, which is much closer to real-world clinical diagnosis than existing LLMs.




Figure 2: Comparison between our DxDirector-7B and existing LLMs in full-process clinic diagnosis. **(a)**. Existing LLMs are still limited to answering questions with complete clinical information. **(b)**. However, the real-world clinical diagnosis only begins with the patient’s vague and nonspecialist chief complaint. This gap makes that LLMs can only provide assistance in making final diagnosis while much more work before this still highly relies on human physicians. **(c)**. Our DxDirector-7B addresses this by driving the full-process clinical diagnosis step-by-step, only requesting assistance from physicians at necessary steps with the principle of minimizing physicians’ involvement.

In Fig. 2 (c), DxDirector-7B systematically executes complex clinical diagnosis in a stepwise manner, interconnected by a detailed reasoning process—termed “deep thinking”—that mimics human “slow thinking” cognitive strategy. This deep thinking incorporates current clinical data and integrates overarching diagnostic objectives, guiding the identification of critical questions at each diagnostic stage (denoted as “[Question]” in Fig. 3). If the question requires objective medical knowledge or inference (automatically marked with “<LLM>”), DxDirector-7B will generate the answer to the question by itself. If the question requires clinical operations for diagnostic test, such as medical imaging, physical examinations, laboratory tests that computer program-based LLMs cannot complete, it will actively request assistance from human physicians (automatically marked with “<Physician>”), who will input the results of the operation as an answer. The deep thinking at each step ensures that the step is correct and efficient, so that the diagnosis can be completed accurately while relying on the minimal human physicians’ efforts.

When DxDirector-7B determines that the diagnosis is complete, it synthesizes the preceding steps into a succinct summary (“[Final Diagnosis]” in Fig. 3). It can attach the authoritative medical literature retrieved by a medical search model or physicians’ operations involved in each step. This improves the verifiability of the generated diagnosis at fine-grained level. Additionally, it clearly delineates the actions of LLMs and physicians to establish a precise accountability framework, which is critical in potential medical incidents. More practical cases are in Extended Data Fig. 17 to Fig. 22.

Compared to existing state-of-the-art LLMs, DxDirector-7B achieves superior diagnostic accuracy while markedly reducing both the clinical workload and expertise required of human physicians. As discussed in Fig. 1, the development of DxDirector-7B signals a paradigm shift in clinical practice, fundamentally redefining the collaborative dynamics between AI and healthcare professionals and providing an efficient, accurate and scalable diagnostic solution.

### 2.1.2 Training Method

Our training method for DxDirector-7B includes three stages: (1) Continued pre-training on medical data; (2) Instruction-tuning for full-process diagnosis; (3) Step-level strategy preference optimization.

The first stage is consistent with existing medical-adaptation methods for LLMs [7, 22]. We continued pre-train Llama-2-7B [39] on large-scale medical data such as clinical guidelines, PubMed papers, and so on. This stage enables the general LLMs to acquire medical knowledge, which forms the foundation for its clinical diagnosis capabilities. Details about this can be found in Section 4.1.

The second stage is instruction-tuning for full-process clinical diagnosis. This stage enables our DxDirector-7B to drive the full-process clinical diagnosis solely starting with ambiguous chief complaints, through the step-by-step reasoning and continuous deep thinking. The training dataset



Figure 3: A case of DxDirector-7B performing the full-process diagnosis starting with only a chief complaint. Most of this process is driven by DxDirector-7B step-by-step reasoning (green texts) and physicians only need to follow its instructions to complete some basic clinical operations (blue texts).

is constructed based on publicly available medical question-answering data [16]. We use general-purpose LLM GPT-4o to convert patients' case reports in the datasets into step-by-step reasoning, and use powerful reasoning LLM o1-preview to enrich the thinking process of each step (details of this can be found in Section 4.2). The automated construction process of this synthetic data is supervised by medical experts. After data construction, we get 10,178 high-quality instruction-response pairs covering multiple clinical tasks such as diagnosis, differential diagnosis, designing treatment plan, screening, analyzing etiology, and so on. Instruction tuning based on this dataset endows our DxDirector-7B with the preliminary capability to drive a full-process clinical diagnosis and perform deep thinking. The technical details of training can be found in Section 4.2.

The third stage is step-level strategy preference optimization. We call the question to be solved in each step derived by deep thinking of DxDirector-7B as "strategy". After the second stage, our DxDirector-7B can generate the strategy step-by-step just like Fig. 2 (c). The third stage enables DxDirector-7B to implicitly compare multiple potential strategies in deep thinking at each step and select the optimal strategy. This ensures that each step in complex clinical reasoning is correct and efficient, so that the diagnosis can be completed accurately while relying on the minimal human physicians' efforts. The optimization of this stage is performed at step-level. In training data construction, we use multiple sampling to make DxDirector-7B generate multiple different strategies for each step (given the same

prefix) and assign different rewards to these strategies. The reward value is determined by both the correctness of the final answer and the quantified physician workload derived from the strategies. Strategies with more correct answers are assigned higher rewards. For strategies with the same correct answers, the strategies that seek more assistance from human physicians will have a lower reward value. In training, DxDirector-7B learns to refine deep thinking to generate the strategy with the highest reward by reward-based reinforcement learning [42] with the principle of ensuring correctness while minimizing the workload of human physicians. Details can be found in Section 4.3.

## 2.2 Overview of Experiments

**Evaluation Datasets** The evaluation datasets consist of two parts: one is four publicly available medical datasets evaluated automatically based on their provided correct answers, and the other is set of cases in real-world clinical diagnosis with the evaluation participated by medical specialists.

For the publicly available datasets, we first collect raw data and then reconstruct them to simulate full-process clinical diagnosis scenarios, in which LLM is initially only provided with the patient’s chief complaint while additional clinical information that helps make the definitive diagnosis needs to be gradually inferred or obtained through its active reasoning process. Four datasets are utilized: (1) **NEJM Clinicopathologic Cases** [4], it covers 344 clinical cases published by the New England Journal of Medicine between 2014 and 2024. These cases are highly complex, rare, and educationally significant. (2) **RareArena**<sup>2</sup> is a dataset of nearly 50,000 rare disease diagnoses extracted from case summaries in PubMed Central, covering 4,597 rare disease types. We use the rare disease confirmation of it, which covers 22,901 data samples. (3) **ClinicalBench** [46] is a multi-departmental clinical diagnostic evaluation benchmark includes 1,500 real-world cases that cover 150 diseases. (4) **US Medical License Exam** [16], it is a set of 1,273 challenging medical questions in the US Medical License Exam. There are many tasks in this dataset such as diagnosis, differential diagnosis, treatment planning, and so on.

To simulate the full-process clinical diagnosis beginning with only a patient’s initial chief complaint, we reconstruct the four datasets as follows. For each data instance, we first employ GPT-4o API<sup>3</sup> to extract all clinical information (patient’s profile, disease symptoms and histories, drug dosage requirements, diagnostic test results, and so on.). Next, we utilize GPT-4o API to transform medically precise clinical descriptions into vague chief complaints characteristic of real patients. Both steps leverage the in-context learning approach[10], guided by explicit instructions and exemplar cases curated by medical experts. In this way, each data instance is reformulated as a triplet comprising a clinical diagnostic question, an initial patient chief complaint, and detailed clinical information. At the beginning of the diagnosis, LLMs can only access the chief complaint, while additional clinical information needs to be gradually inferred or obtained through its active reasoning.

For the real-world clinical diagnosis, we construct real clinical diagnostic scenario within an officially certified Grade 3A hospital in China<sup>4</sup>. This evaluation covers 160 real cases across 9 different clinical departments. We introduce the medical specialists in each department to participate in the evaluation of the diagnostic results generated by LLMs. The specific details about this can be found in Section 2.6. This experiment has been approved by the hospital’s Ethics Review Committee (IRB00006761-M20250173). To safeguard patient privacy, any personally identifiable information (PII) or other sensitive details have been manually identified and removed by the medical team.

**Full-process Clinical Diagnosis Setting for Evaluation** Based on above datasets, we construct a full-process clinical diagnosis setting to evaluate the performance of various LLMs. In this setting, each data instance consists of a question, a patient’s chief complaint and detailed clinical information. Initially, the LLM has access solely to the chief complaint and is tasked with addressing questions related to diagnosis, treatment strategies, etiology, and so on. Any additional clinical details must subsequently be inferred or actively obtained through stepwise reasoning. When encountering tasks need clinical operations that the computer program cannot complete, such as symptom observation, laboratory testing, physical examination, and so on, the LLM proactively requests assistance from human physicians. To automatically simulate this physician interaction on large-scale dataset, we implement an AI agent powered by GPT-4o, which receives real-time queries from the LLM, interprets the requested clinical information, and provides relevant data extracted from detailed clinical information to LLM, allowing LLM to continue reasoning. This framework effectively

<sup>2</sup><https://github.com/zhao-zy15/RareArena>

<sup>3</sup><https://api.openai.com/v1/chat/completions>.

<sup>4</sup>Grade 3A hospitals are the highest level hospitals in China’s “three-grade, six-class” classification system.

replicates realistic interactions in full-process clinical diagnosis, where LLM asks the assistance from physicians. Our DxDirector-7B has ability to actively perform full-process clinical diagnosis for patient’s chief complaint while all baselines do not. Because existing LLMs tend to directly make a diagnosis, even when the current clinical information is vague and insufficient (as shown in Fig 2 (a) and (b)). So we design specific prompts (Supplementary Fig. 21) to guide the baselines in completing this with multi-round conversation between themselves and the simulated physicians.

**Baselines** The baselines in the experiments can be divided into two categories:

1. One is the current most powerful commercial general-purpose large language models including Deepseek-v3-671B [21], GPT-4o [1], OpenAI o1-preview [15], OpenAI o3-mini<sup>5</sup>, Gemini-2.0-flash [36]. These LLMs boast hundreds of billions of parameters and are developed by tech giants (OpenAI, Google, Microsoft and Deepseek) at immense training costs. Recent study has shown that they have promising performance in making the final clinical diagnosis [4, 19].
2. The other is the open source LLMs specifically optimized for medical domain including Meditron-70B [7], OpenbioLLM-70B<sup>6</sup>, Clinical Camel-70B [38] and Meditron-176B [22] and a open source general LLM Llama-3-70B [13]. They have significantly larger parameters than our DxDirector-7B (70B, 176B vs. our 7B), which means they are more expensive to train and infer.

### 2.3 Accuracy of Clinical Diagnosis


This section reports the experimental results about clinical diagnostic accuracy of various LLMs on NEJM Clinicopathologic Cases, RareArena and ClinicalBench in full-process diagnosis setting. Our DxDirector-7B achieves the highest accuracy on all these three datasets and outperforms human physicians on complex cases. The detailed results and analysis are as follows.

The evaluation on RareArena reveals the capacity of LLMs to diagnose rare diseases—a challenging domain that requires expertise in conditions characterized by low prevalence, encompassing 4,597 distinct pathologies across 22,901 clinical cases. As illustrated in Fig.4a, under the full-process diagnostic setting, our DxDirector-7B achieves the highest accuracy at 36.23%. This represents a 3.27% absolute advantage over the strongest commercial LLM (o3-mini: 32.96%) and a 12.25% lead against medically adapted LLMs (MedFound-176B: 23.98%), despite using 25 times fewer parameters than medically adapted LLMs and nearly 100 times fewer than commercial LLMs like Deepseek-V3-671B (27.03%). Besides, the stark contrast between commercial LLMs highlights reasoning’s critical role—GPT-4o (24.07%) underperforms o3-mini by 8.89% and o1-preview (30.20%) by 6.13%, despite comparable medical knowledge memorization. Both o1-preview and o3-min are LLMs with powerful reasoning ability. This suggests that stronger logical reasoning enables better synthesis of sparse symptom patterns in rare disease diagnosis, a capability GPT-4o lacks despite superior general intelligence [29]. Our DxDirector-7B amplifies this advantage through deep thinking like human at each step, achieving higher parameter efficiency while delivering superior accuracy.


The evaluation on NEJM Clinicopathologic Cases benchmark reveals critical insights into the capabilities and limitations of LLMs in complex clinical reasoning. Fig. 4b presents the diagnostic accuracy of baselines and our DxDirector-7B in the setting of full-process clinical diagnosis. Our DxDirector-7B achieves the best accuracy (38.4%) and outperforms human physicians. Further analysis reveals three pivotal findings. First, existing medical-domain adaptation methods of LLMs provides limited benefits on full-process diagnosis: LLMs pretrained on large-scale medical data (Meditron-70B: 23.17%; OpenbioLLM-70B: 26.80%; MedFound-176B: 26.38%) show marginal gains over the generalist Llama-3-70B (25.20%) at equivalent (70B) or even more (176B) parameters ( $\Delta \leq 1.60\%$ ). Second, while trillion-parameter commercial general-purpose LLMs (GPT-4o: 30.8%; Deepseek-V3-671B: 29.2%) surpass medically adapted LLMs, all remain statistically inferior to human physicians (32.5%), exposing fundamental limitations in existing LLMs for full-process clinical diagnosis. Third, DxDirector-7B achieves the best accuracy—a 5.9% absolute improvement over physicians and 7.6% over GPT-4o—despite using merely 4%–10% parameters of medically adapted LLMs (7B vs. 70B, 176B) and nearly 1% of commercial general-purpose LLMs. This demonstrates the effectiveness and efficiency of our training method in allowing LLMs to think deeply like “slow thinking” at each reasoning step, which enables human-surpassing diagnostic accuracy. The results redefine optimization strategies for medical LLMs, proving that lightweight models with powerful deep thinking ability can master complex full-process clinical reasoning, rather than brute-force scaling or narrow pretraining on large scale medical data.

<sup>5</sup><https://openai.com/index/o3-mini-system-card/>


<sup>6</sup><https://huggingface.co/aaditya/Llama3-OpenBioLLM-70B#>



(a) Rare Disease Cases (RareArena).



(b) Complex Cases (NEJM Clinicopathologic Cases). Accuracy of human physician is from [4].



(c) Real-world Cases (ClinicalBench).

Figure 4: Accuracy of diagnoses generated by different LLMs across different datasets in full-process diagnosis setting. Bars are annotated with the accuracy of each LLM. Error bars reflect 95% confidence intervals determined by non-parametric bootstrap procedure with 1,000 samples on RareArena and ClinicalBench, and 200 samples on NEJM Cases. We perform statistical significance tests utilizing the two-side McNemar test between DxDirector-7B and the top-3 baselines on each dataset, with p-value levels annotated on the bars.

The ClinicalBench—spanning 1,500 real-world cases across 150 diseases—reveals the performance of LLMs in real-world full-process clinical diagnosis. Results in Fig.4c show DxDirector-7B achieves the highest accuracy at 63.46%, outperforming the strongest commercial model (Deepseek-V3-671B: 46.66%) by 16.8% and medically adapted LLMs (Clinical Camel-70B: 31.43%; OpenbioLLM-70B: 32.86%; MedFound-176B: 35.76%) by 27.70% to 32.03%, despite using much fewer parameters. In addition to the conclusions consistent with NEJM and RareArena, the results on ClinicalBench suggest two important findings: first, compared to NEJM and RareArena, our DxDirector-7B achieves the largest absolute improvement, which shows the significant advantages of our DxDirector-7B in real-world diagnosis. Second, sole medical-domain training of LLMs cannot be efficiently translated to full-process diagnosis in clinical practice, as OpenbioLLM-70B (32.86%) and MedFound-176B (35.76%) shows worse performance than general LLM Llama-3-70B (38.86%). This indicates “slow thinking” plays a more important role than sole medical adaptation in driving full-process diagnosis.


## 2.4 Quantitative Analysis of Human Physicians’ Workload

This section analyzes the workload needed to be paid by human physicians when LLMs drive the full-process clinical diagnostic. In our constructed AI-driven full-process clinical diagnosis setting, to maximize the potential of LLMs and reduce the workload of human physicians as much as possible, human physicians only need to work as assistants to follow the instructions of LLMs to complete clinical operations that LLMs cannot achieve, such as observing symptoms, physical examinations, laboratory tests, and so on. An ideal LLM should be capable of precisely identifying the essential clinical tasks that truly require human intervention, adhering to the principle of minimizing physician involvement while ensuring diagnostic accuracy. To quantitatively assess this, we introduce two key metrics: (1) the total number of clinical operations that the LLM requests physicians to perform throughout the diagnostic process (where fewer requests indicate greater efficiency), and (2) the proportion of operations that are truly useful for making an accurate diagnosis out of all requested operations. (the higher the better). The specific clinical operations required by LLMs can be found in word cloud analysis of Supplementary Fig. 1 to Fig. 10.


Combining the findings in Section 2.3 and 2.4, in the full-process diagnostic setting, our DxDirector-7B not only achieves significant superior diagnostic accuracy but also substantially reduces physician workload than state-of-the-art LLMs, indicating the efficient, accurate and scalable diagnostic solution. The detailed results and analysis are as follows.

For the first metric, the average statistical results over three datasets are shown in Fig. 5a, 5b and 5c. Specifically, DxDirector-7B effectively complete the entire diagnostic process with an average of approximately 3 clinical operations across diverse diagnostic scenarios, including rare diseases (RareArena), complex cases (NEJM), and real-world clinical contexts (ClinicalBench). This efficiency notably surpass that of all baseline LLMs. By comparison, general-purpose commercial LLMs typically necessitate between 4 and 8 operations, while open-source medically adapted LLMs exhibit the poorest performance, often requiring nearly 10 clinical operations. Within baseline comparisons, commercial general-purpose LLMs such as o3-mini and o1-preview, benefiting from robust reasoning capabilities, consistently require fewer operations than other LLMs, including GPT-4o. Enhanced reasoning capacity allows these LLMs to effectively leverage available clinical data to make accurate clinical decision, thus minimizing additional operational demands—an attribute particularly exemplified by our DxDirector-7B that can perform “slow thinking” like human before making the specific strategy at each diagnostic step.


For the second metric, we determine whether an operation genuinely contributes to diagnosis by assessing whether it appears in the case report provided by medical specialists. This metric serves as an indicator of the LLMs’ proficiency in discerning essential operations necessary for accurate diagnosis while avoiding any redundant operations, with higher values reflecting greater efficiency in engaging human physician assistance. Experimental results across three datasets are presented in Fig. 6a, 6b, and 6c. DxDirector-7B demonstrates consistently superior performance, achieving efficiency ranging from 97% to 98% across all datasets, significantly surpassing the baselines. The performance of the baselines varies. In the diagnosis of complex cases (NEJM), general-purpose LLMs consistently outperform medically adapted LLMs, whereas in the diagnosis of rare diseases (RareArena), medically adapted LLMs surpass general-purpose LLMs. This indicates that the improvement on efficiency in seeking human physicians’ assistance is jointly driven by reasoning capabilities and the retention of long-tail medical knowledge. General-purpose commercial LLMs excel in the former, while medically adapted LLMs excel in the latter.



(a) Rare Disease Cases (RareArena).




(b) Complex Cases (NEJM Clinicopathologic Cases).




(c) Real-world Cases (ClinicalBench).

Figure 5: Number of clinical operations that LLMs request physicians to perform in the entire diagnosis process (the fewer the better). Error bars reflect 95% confidence intervals determined by non-parametric bootstrap procedure with 1,000 samples on RareArena and ClinicalBench, and 200 samples on NEJM Cases. We perform statistical significance tests utilizing two-side Mann-Whitney U test between DxDirector-7B and the top-3 baselines, with p-value levels annotated on the bars.



(a) Rare Disease Cases (RareArena).



(b) Complex Cases (NEJM Clinicopathologic Cases).




Figure 6: Proportion of operations that are truly useful for making a diagnosis out of all requested operations. (the higher the better). Error bars reflect 95% confidence intervals determined by non-parametric bootstrap procedure with 1,000 samples on RareArena and ClinicalBench, and 200 samples on NEJM Cases. We perform statistical significance tests utilizing two-side Mann-Whitney U test between DxDirector-7B and the top-3 baselines, with p-value levels annotated on the bars.

## 2.5 Department-level Fine-grained Evaluations

In this part, we categorize the data from ClinicalBench and RareArena by clinical department and assess the diagnostic accuracy within each category, providing a more granular evaluation of LLMs.




Figure 7: A comparative heatmap analysis of diagnostic accuracy: DxDirector-7B vs. state-of-the-art medically adapted and commercial general-purpose LLMs across 17 clinical departments consisting of 1,500 samples in ClinicalBench that is collected from real world. **Bold** indicates the best performance.

The heat map in Fig. 7 illustrates the diagnostic accuracy across 17 clinical departments comprising 1,500 real-world cases within ClinicalBench. Our DxDirector-7B achieves the best performance on 14 out of 17 departments. ClinicalBench can reflect the true clinical distribution encountered in routine practice. DxDirector-7B significantly outperforms all baseline LLMs, with substantial margins observed particularly in Neurosurgery ( $\Delta = 40.0\%$ ), Oncology ( $\Delta = 30.93\%$ ) and Pulmonology




Figure 8: A comparative heatmap analysis of diagnostic accuracy: DxDirector-7B vs. state-of-the-art medically adapted and commercial general-purpose LLMs across 19 clinical departments in rare disease cases on 22,901 samples in RareArena. **Bold** indicates the best performance.

( $\Delta = 28.72\%$ ). Diagnoses within these departments typically necessitate comprehensive integration of multiple diagnostic tests. It is a challenging scenario for existing state-of-the-art LLMs, which struggle to actively pursue and integrate necessary diagnostic information starting from only vague patient chief complaints. DxDirector-7B cannot achieve the best performance on Dermatology, Plastic Surgery and Psychiatry. It mainly because that the clinical diagnosis of these three departments is extremely dependent on frequent real contact, observation, and interactions between human physicians and patients, which cannot give full play to the advantages of DxDirector-7B.

The heat map in Fig. 8 illustrates the diagnostic accuracy across 19 clinical departments for rare disease diagnosis, based on 22,901 samples from RareArena. Notably, our DxDirector-7B, outperforms all baselines in 16 out of 19 departments. In particular, DxDirector-7B demonstrates substantial improvements in diagnostic accuracy for rare diseases in Hematology ( $\Delta = 14.84\%$ ), Orthopedics ( $\Delta = 13.64\%$ ), Oncology ( $\Delta = 9.76\%$ ), Pulmonology ( $\Delta = 7.33\%$ ), and Infectious Diseases ( $\Delta = 7.1\%$ ). The diagnosis of rare diseases in these departments emphasizes that LLMs can accurately plan and integrate diagnostic tests at multiple stages, integrate travel and contact history with laboratory results, and perform image-test collaborative reasoning. These capabilities are the core of LLMs in driving full-process clinical diagnosis, demonstrating the superiority of our DxDirector-7B in this regard. DxDirector-7B cannot surpass Deepseek-v3-671B on Urology ( $\Delta = -5.56\%$ ) and Nephrology ( $\Delta = -7.14\%$ ). Given the overlap in medical knowledge related to the urinary system and kidney function between these two departments, this limitation suggests that DxDirector-7B may have gaps in its long-tail medical knowledge concerning rare diseases in these domains. This analysis shows the strengths and limitations of our DxDirector-7B compared to state-of-the-art LLMs in clinical diagnosis across various departments.

## 2.6 Evaluations on Real-world Clinical Diagnosis

In this section, we introduce medical specialists to participate in the evaluation of LLMs in real-world clinical diagnosis scenarios. The real clinical diagnostic scenario is set within an officially certified Grade 3A hospitals in China. The involved patients are inpatients presenting with more complex conditions than typical outpatients. Consequently, LLMs must engage in intricate reasoning to gather comprehensive clinical information effectively. To safeguard patients from potential harm, the evaluation environment is structured as follows: patient behaviors and medical specialist operations during clinical diagnosis are fully recorded using actual inpatient records. Subsequently, two GPT-4o-based agents replicate precisely the recorded behaviors of patients and specialists throughout the diagnostic process. In evaluation, LLMs interact with these agents to drive the full-process diagnosis, initiating solely from the patient’s vague chief complaint. Within this controlled environment, LLMs do not directly interact with real patients, and their diagnostic outputs undergo rigorous review by medical specialists, thereby effectively mitigating ethical risks and potential harm.

This evaluation is performed on 160 cases across 9 different clinical departments including Gastroenterology, Nephrology, Dermatology, Cardiovascular Medicine, Infectious Diseases, Endocrinology, Pulmonology, General Surgery, and Pain Management. We compare our DxDirector-7B with the most powerful commercial LLMs including GPT-4o, o1-preview, o3-mini and Deepseek-V3-671B, which possess tens of times more parameters than our DxDirector-7B. Medical specialists from each department participate in evaluating the diagnostic contents produced by these LLMs. This evaluation is conducted from two aspects: (1) scoring the diagnostic content generated by LLMs (on a scale from 0 to 10), and (2) assessing whether the diagnoses generated by LLMs could fully replace those made by medical specialists. To ensure objective assessments and mitigate potential biases in human specialists scoring, a double-blind adjudication approach is implemented. In this approach, both human specialists and LLMs independently diagnose the same patient cases without exposure to each other’s diagnostic outputs. Additionally, a third-party evaluation agent, utilizing both GPT-4o and Deepseek-V3, assigns scores based on the alignment between LLM-generated diagnoses and those provided by medical specialists. The final score is calculated as the average of the scores given by GPT-4o and Deepseek-V3, thus ensuring robust and unbiased comparative assessment. The assessment of whether the diagnoses generated by LLMs could replace those made by specialists also follows the same pattern by observing the decisions of the third party agent (can or cannot).

The results of the first aspect are shown in Fig. 9 and Fig. 10. Overall, our DxDirector-7B achieves the highest alignment with medical specialists in all 9 clinical departments, which demonstrates that DxDirector-7B has greater usability and accuracy compared to the most advanced commercial LLMs in real-world clinical practice. The significant lead is evident in Cardiovascular, Pulmonology, and




Figure 9: A comparison of the capabilities of different LLMs in 9 departments in real-world clinical diagnosis. The evaluation is conducted by double-blinded adjudication between LLMs and specialists in the corresponding departments, with scores ranging from 0 to 10. We perform statistical significance tests utilizing the two-side Mann-Whitney U test between DxDirector-7B and the baselines, with p-value levels annotated on the figures.

**Gastroenterology.** In these departments, patients' chief complaints are far from sufficient to determine the final diagnosis, requiring additional diagnostic test results such as CT scans, angiography, blood tests, and more. These necessitate LLMs to actively acquire the complete clinical information by step-by-step reasoning to finish the entire diagnostic process, posing a substantial challenge for existing LLMs and our DxDirector-7B can effectively address.

The results of the second aspect are shown in Fig. 11. In this evaluation, the third-party agent assesses whether the diagnoses generated by DxDirector-7B could replace those made by medical specialists. In the bar of Fig. 11, the proportion of various LLMs indicates the ratio of samples that LLMs can replace specialist physicians to the total number of samples. All baseline LLMs fail to outperform specialist physicians in all departments. On the contrary, as for our DxDirector-7B, the diagnostic




Figure 10: A comparison of the capabilities of different LLMs in 9 departments in real-world clinical diagnosis. The evaluation is conducted by double-blinded adjudication between LLMs and specialists in the corresponding departments, with scores ranging from 0 to 10.

contents generated by DxDirector-7B in cardiovascular medicine achieves a 75.0% replacement rate to specialist physicians. In infectious diseases, gastroenterology, pain management, pulmonology and endocrinology, DxDirector-7B achieves 60%–66.7% replacement rate to specialist physicians. These departments emphasize the comprehensive analysis and reasoning of clinical testing information. For departments such as dermatology and general surgery where physical operations such as contact, observation, and real-time response are dominant, DxDirector-7B cannot achieve replacement rates of more than 50%, because in real-world clinical diagnosis, these departments strongly rely on frequent real interactions with human physicians and patients.

## 2.7 Evaluations on US Medical License Exam Consisting of Various Clinical Tasks

In this section, we assess the performance of LLMs using the United States Medical Licensing Examination (USMLE) dataset, which comprises 1,273 publicly available cases covering various clinical tasks, such as diagnosis, differential diagnosis, prevention, etiological analysis, and so on. To better replicate realistic clinical scenarios and elevate the complexity, we convert the original multiple-choice format of the USMLE questions into open-ended questions. This transformation demands more sophisticated reasoning and clinical inference from the LLMs. In this transformed dataset, LLMs are required to address questions across various tasks under full-process diagnosis setting. Here, only the patient’s chief complaint is initially provided, and the LLMs must actively infer and gather more detailed clinical information through more reasoning.

**Overall Accuracy** The overall performance of various LLMs on the US Medical Licensing Examination (USMLE) is illustrated in Fig. 12. Our DxDirector-7B achieves the highest accuracy (50.88%), underscoring its superior capabilities not only in making diagnosis but also across a broader array of clinical tasks, thereby highlighting its versatility for practical healthcare applications. Notably, DxDirector-7B outperforms medically adapted LLMs such as MedFound-176B, attaining a significant absolute improvement of 11.85% despite having only approximately one-tenth of the parameter size




Figure 11: The proportion of the diagnoses generated by LLMs can completely replace those of medical specialists in each department. The assessment is conducted by double-blinded adjudication between LLMs and specialists in the corresponding department.

(7B compared to 70B and 176B). Furthermore, medically adapted LLMs with similar parameter sizes (OpenbioLLM-70B, Clinical Camel-70B, and Meditron-70B) demonstrate inferior performance (by  $\Delta = -6.84\% \sim -3.92\%$ ) compared to the general LLM Llama-3-70B. This observation suggests that existing medical adaptation methods, while effective at enhancing diagnostic accuracy, may inadvertently compromise performance on other critical tasks in full-process clinical diagnosis setting. Collectively, these comparisons emphasize the efficacy and generalizability of our training method employed in developing DxDirector-7B.

**Specific Accuracy on Twelve Clinical Tasks** Fig. 13 provides a detailed comparison of the performance of various LLMs across 12 clinical tasks within the USMLE dataset, offering granular insight into their comprehensive clinical capabilities in full-process diagnosis. Our DxDirector-7B outperforms all powerful commercial LLMs on 10 out of 12 tasks. Specifically, DxDirector-7B




Figure 12: Accuracy of answering questions about various clinical tasks on US Medical License Exam in full-process diagnosis setting. Bars are annotated with the accuracy of each LLM. Error bars reflect 95% confidence intervals determined by non-parametric bootstrap procedure with 1,000 samples. We perform statistical significance tests utilizing the two-side McNemar test between DxDirector-7B and the top-3 baseline, with p-value levels annotated on the bars.




Figure 13: The visual comparison among various LLMs on 12 clinical tasks in USMLE.

achieves the large absolute improvement than all baselines in differential diagnosis ( $\Delta = 18.00\%$ ) and etiology ( $\Delta = 10.13\%$ ). Both of these two tasks require LLMs to obtain as detailed and accurate clinical test information as possible to rule out potential disease options and determine the etiology. So our DxDirector-7B, equipped with strong full-process diagnostic driving capability, significantly outperforms other LLMs in this regard. DxDirector-7B performs worse than Deepseek-V3-671B in basic science integration, this is primarily due to the substantial gap in the number of parameters




Figure 14: The effectiveness of the accountability mechanism for the diagnosis content generated by different LLMs in misdiagnosis scenarios. This is a classification task with 3 classes including the responsibilities of LLMs, human physicians or both of them. We use precision and recall for each task as the evaluation metrics. For example, bars for LLM class means the recall and precision for identifying the misdiagnoses caused by LLMs. Error bars reflect 95% confidence intervals determined by non-parametric bootstrap procedure with 1,000 samples.

between the two (nearly 100 times), which renders DxDirector-7B’s ability to memorize basic medical knowledge comparatively weaker. Besides, GPT-4o with powerful chat capabilities is better than DxDirector-7B in patient communication. Compared with other tasks, basic science integration and patient communication are not strongly dependent on the ability to drive the entire diagnostic process, so these two are not specially optimized in DxDirector-7B. Overall, our DxDirector-7B has surpassed the existing strongest commercial LLMs on most critical clinical tasks in full-process diagnosis setting, despite having a significantly lower parameter count and training cost.

## 2.8 Accountability in Misdiagnosis

In this section, we evaluate the accountability of DxDirector-7B in cases of misdiagnosis. Unlike existing LLMs, which present the entire diagnostic reasoning process interwoven with multiple human physician operations without clear distinction, DxDirector-7B explicitly structures the diagnostic process (Fig. 3). Each diagnostic step is clearly itemized, distinguishing the content generated by the LLM from that provided by human physicians, and each LLM-generated step is explicitly attached by authoritative medical literature. This structured approach enables precise identification of specific erroneous steps during a misdiagnosis and clarifies responsibility between the LLM and physicians.

To evaluate the accountability capability of DxDirector-7B in cases of misdiagnosis, we simulate diagnostic errors by introducing perturbations to randomly selected steps within the diagnostic process to make LLM generate the incorrect diagnosis. The specific perturbation method is employing Deepseek-V3 to rewrite the selected steps to generate new content that is factually inconsistent with the original content. These perturbations can impact either the LLM-generated content, the involvement of human physicians, or both. In this scenario, a GPT-4o-based agent is employed to assess whether it can correctly identify the source of misdiagnosis—whether attributed to human physicians, LLMs, or both—thereby evaluating the effectiveness of the accountability mechanism. This evaluation constitutes a three-class classification task, utilizing precision and recall as primary metrics. The evaluation dataset comprises 1,500 sampled cases that all LLMs can generate the correct diagnosis from RareArena and ClinicalBench. Results, presented in Fig. 14, indicate that DxDirector-7B’s accountability mechanism achieves the highest precision and recall across all categories compared to baseline LLMs. Notably, baseline LLMs typically attribute errors disproportionately to human

physicians over LLMs, reflected by higher recall but lower precision for physician accountability than LLM (recall: 78.23% ~ 80.91% vs. 49.35% ~ 53.42%; precision: 60.42% ~ 62.15% vs. 70.40% ~ 71.95%), which means that the diagnostic content generated by baselines makes physicians over-accountable compared to LLMs. In contrast, DxDirector-7B maintains comparable and high precision and recall for both LLM and physician accountability. This means that providing clear and fine-grained content attached by authoritative medical literature is of great significance for achieving an accurate medical accountability mechanism.

### 3 Discussion

**Reverse the Physician-AI Relationship** Existing AI remains largely as an assistant to physician. This AI-assisted working pattern limits AI's ability to fully reduce physicians' workload and enhance diagnostic efficiency. In this paper, we propose an innovative paradigm that reverses the relationship between AI and physicians, that is, training LLM to be a director in the entire process of clinical diagnosis, while physicians become assistants of the LLM, providing simple help only when necessary with the principle of minimizing physicians' involvement. It advances effective AI deployment in full-process clinical workflows of the real world, reducing the workload of physicians to the greatest extent possible and indicating the efficient, accurate and scalable diagnostic solution.

**Superior Diagnostic Accuracy in Full-process Clinical Diagnosis Setting** Based on above design, we propose DxDirector-7B, an LLM with powerful deep thinking ability, can effectively drive the full-process clinical diagnosis with the minimal human efforts to reduce the workload and lessen the demand for specialized expertise of human physicians in practical clinical tasks as much as possible. We evaluate our DxDirector-7B in full-process setting across four publicly authoritative datasets including rare and complex cases, and a real-world clinical diagnostic scenario set in a top-tier hospital in China. As for accuracy of diagnosis, experimental results in Fig. 4, Fig. 9 and Fig. 12 indicate that our DxDirector-7B significantly surpasses the medically adapted LLMs with dozens of times more parameters, such as MedFound-176B and commercial general-purpose LLMs with nearly 100 times more parameters, such as GPT-4o, o1-preview, o3-mini, and Deepseek-V3-671B. This means that our DxDirector-7B is not only accurate but computationally economical, which is a solid step towards the low-cost and effective application of LLMs in practical clinical diagnostics.

**Significantly Reduce the Physician Workload** The workload human physicians need to pay in full-process diagnosis is crucial metrics for evaluating the empowerment of AI in clinical diagnosis. Experimental results in Fig. 5 and Fig. 6 show that in the entire process of clinical diagnosis, our DxDirector-7B achieves the minimal physicians' workload, the maximum physicians' efficiency and the most accurate diagnosis compared with existing state-of-the-art LLMs. This means DxDirector-7B is an efficient, accurate and scalable diagnostic solution.

**Comprehensive Understanding at Department-Level** In order to gain a more comprehensive understanding of the advantages and disadvantages of our DxDirector-7B across different clinical departments. We report the comparison between DxDirector-7B and baselines at the departmental level in Fig. 7 (17 departments, real-world cases) and Fig. 8 (19 departments, rare diseases). The results indicate that our DxDirector-7B achieves significant superior diagnostic accuracy on most departments than all powerful baselines, especially on departments that are complex and require many diagnostic tests, such as oncology. This means DxDirector-7B has more powerful ability to drive multiple appropriate diagnostic tests in full-process clinical diagnosis to iteratively enrich the clinical information for accurate diagnosis, which is because DxDirector-7B can continuously perform deep thinking to make the optimal decision. This emphasizes the importance of developing LLMs with greater deep thinking abilities for clinical diagnosis.

**Promisingly Substitute Medical Specialists in Real-World diagnosis** Experiments on real-world cases across 9 clinical departments in top-tier hospital in China further demonstrate the advantages of our DxDirector-7B in practical clinical diagnostic applications (Fig. 9). Evaluations with the participation of human medical specialists show that the diagnoses generated by our DxDirector-7B achieve substitution for human medical specialists in 60% to 75% of cases in many departments (Fig. 11). This results surpass all state-of-the-art LLMs and indicate the potential of DxDirector-7B to serve as a viable substitute for medical specialist in real-world diagnosis.

**Superior Performance on Various Clinical Tasks** Making a diagnosis is not the only task in clinical practice. We further evaluate LLMs on 12 clinical tasks (differential diagnosis, treatment, etiology and so on.) at US Medical License Exam level. Our DxDirector-7B outperforms all powerful commercial LLMs on 10 out of 12 tasks, especially achieves significant improvement on the tasks

that require LLMs to obtain as detailed and accurate clinical test information as possible, such as differential diagnosis and etiology. DxDirector-7B is expected to become an all-around director in clinical diagnosis, accurately completing various clinical tasks by minimizing the need for assistance from human doctors.

**Accurate Accountability Mechanism** Establishing a clear and accurate accountability mechanism between human physicians and AI for misdiagnosis is very important at a time when both parties are working closely together. Our DxDirector-7B generates the clear diagnosis (Fig. 3) in which each step is listed separately item by item, the content generated by LLM is clearly distinguished from the human physicians, and each step generated by LLM is attached by authoritative medical literature. This structured output provides a basis for clearly identifying the specific erroneous medical steps and distinguishing the responsibilities between physicians and LLMs in a misdiagnosis. Evaluation on a large misdiagnosis dataset shows that compared with all powerfull LLMs in baselines, the diagnoses generated by DxDirector-7B can provide a more accurate and fair mechanism for accountability in misdiagnosis.

**Value and Impact** These results show our DxDirector-7B successfully reshapes the collaborative relationship between AI and human physicians, which indicates the new era where AI, traditionally has always been regarded as a physician’s assistant, now assumes a director role in autonomously steering the entire diagnostic process with the principle of minimizing the physician’s involvement. This paradigm shift is designed to substantially alleviate the workload of human physicians, enhancing efficiency while improving diagnostic accuracy. DxDirector-7B significantly reduces the reliance on human physicians’ workload and professional expertise, thus lowering barriers to quality medical diagnosis. By delivering a low-cost, efficient, and accurate clinical solution, DxDirector-7B offers profound implications, particularly for medically underserved and resource-limited regions and is promising to be applied into various clinical departments and tasks. Besides, the significantly lower parameter count and training and inference costs compared to existing state-of-the-art LLMs enable DxDirector-7B to be applied to various medical institutions at low cost.

**Limitations and Future Work** Although our DxDirector-7B has demonstrated impressive performance, there are still some points worth studying in the future. For example, more refined and diversified rules for human physician participation can be defined for each clinical department to further improve efficiency. Besides, the assistants for DxDirector-7B can be not only human physicians but other AI models for healthcare. For example, DxDirector-7B can call on various specialized pathology analysis models with visual understanding capabilities for radiology [23, 49, 8, 35], echocardiography [14], cell slice analysis [6], pathology [5], and so on. This can further reduce the workload of human physicians and improve accuracy. From a higher perspective, DxDirector-7B can act as a director in establishing an efficient diagnostic framework that promotes effective collaboration among the three key entities: physicians, patients, and various specialized AI models. Future exploration in these directions will revolutionize the existing healthcare paradigm. A large language model with exceptional reasoning capabilities will enable the fully automated, efficient mobilization and integration of various medical resources, significantly enhancing both the efficiency and accuracy of healthcare delivery.

## 4 Methods

In this section, we introduce the detailed training method of our DxDirector-7B, which can be divided into three stages: (1) Continued pre-training on medical data; (2) Instruction-tuning for full-process clinical diagnosis; (3) Step-level strategy preference optimization. Then we introduce more details about our experiments.

### 4.1 Continued Pre-training on Medical Data

This stage enables the general LLM to acquire medical knowledge, which forms the foundation for its clinical diagnosis capabilities. Specifically, in this stage, we train open-source LLM (Llama-2-7B) on large-scale medical texts by cross-entropy loss function in the paradigm of next token prediction, being supervised by the learning signals from medical texts themselves. For example, given  $\mathcal{C}$  is a dataset of texts,  $C_i = [c_1, c_2, c_3, \dots, c_n]$  is one of the text sequence in  $\mathcal{C}$  ( $C_i \in \mathcal{C}$ ),  $M(c_t | c_1, c_2, \dots, c_{t-1}; \theta)$  is the probability of  $c_t$  estimated by the LLM given prefix  $[c_1, c_2, \dots, c_{t-1}]$  and model parameters  $\theta$ . the training objective in this continued pre-training stage is minimizing the negative log-likelihood over

set  $\mathcal{C}$  as:

$$\min_{\theta} \sum_{C_t \in \mathcal{C}} \sum_{t=1}^n -\log \mathcal{M}(c_i | c_1, c_2, \dots c_{t-1}; \theta). \quad (1)$$

We collect publicly available medical data for this continued pre-training including 35K articles from clinical guidelines, 16.1M paper abstracts from PubMed and PubMed Central, 5M full papers from PubMed and PubMed Central [7]. Llama-2-7B is trained on these datasets to memorize the basic medical knowledge. Besides, we use experience replay [7] to maintain the original general knowledge of Llama-2-7B by mixing 500K general domain data from Wikipedia, ArXiv, books, and StackExchange into the training datasets.

## 4.2 Instruction-tuning for Full-process Clinical Diagnosis

Instruction-tuning is the process of training the LLM that has been pre-trained to generate expected responses for user’s input instructions [48]. Full-process clinical diagnosis in the real world, especially for rare and complex cases, often involves multiple complex medical knowledge and multiple diagnostic test procedures. This section introduces our proposed novel instruction-tuning method that enables our DxDirector-7B to drive full-process clinical diagnosis solely starting with ambiguous chief complaints, through a step-by-step reasoning and continuous deep thinking. The training at this stage aims to endow DxDirector-7B with four key capabilities:

1. **Progressive Clinical Information Reasoning:** DxDirector-7B can gradually reason valuable clinical information starting with a patient’s vague complaint in a step-by-step manner, ultimately completing clinical tasks such as diagnosis, treatment plan design, and so on. Each step may involve inference about medical knowledge, analyzing clinical phenomena, or designing diagnostic tests.
2. **Step-Level Deep Thinking:** DxDirector-7B possesses deep thinking—that mimics human “slow thinking capabilities at the step level. When determining the specific strategy for each step, it first generates a thinking process that analyzes the currently available information and the expected goal to define the optimal strategy for the current step.
3. **Human Assistance When Necessary:** In cases where the strategy requires clinical operations for diagnostic test—such as medical imaging, physical examinations, laboratory tests, and so on, which computer program-based LLMs cannot complete—DxDirector-7B can request assistance from human physicians and continue reasoning after receiving the assistance.
4. **Autonomously Generate Final Diagnosis:** DxDirector-7B can autonomously decide whether it can make an accurate final diagnosis based on the currently available information. The generated final diagnosis is a concise and clear summary of the step-by-step reasoning process, with each involved medical knowledge attached by authoritative medical literature.

We introduce the details about this stage in two parts: dataset construction and training.

### 4.2.1 Data Construction

Constructing the suitable training dataset is the prerequisite. Our data construction can be divided into three steps: (1) raw data collection, (2) data transformation, and (3) deep thinking injection. The pipeline of our data construction is shown in Fig. 15.

In raw data collection, our raw data is collected from MedQA [16], a medical question-and-answer dataset enriched with extensive context, including detailed clinical information such as patient profiles, disease symptoms and histories, diagnostic test results, vital signs, and so on. Questions in this dataset covers multiple clinical tasks such as diagnosis, differential diagnosis, designing treatment plan, screening, analyzing etiology, and so on. This dataset contains 10,178 samples. After collecting the raw dataset, we perform data transformation on it to construct the data aligning with full-process diagnosis. We use GPT-4o API for fully automated data transformation, and introduce human medical experts perform sample evaluations of the transformed data to ensure the quality. For each data sample, data transformation consists of three steps as shown in “Data Transformation” part in Fig. 15:

Firstly, we use GPT-4o to extract the patient’s detailed clinical information from the context, such as symptoms, medical history, all diagnostic test results, and vital signs, and so on. In full-process




Figure 15: Pipeline of our data construction for instruction-tuning for full-process clinical diagnosis.

clinical diagnosis, this information cannot be obtained at the beginning, but is gradually obtained during the complex consultation process.

Secondly, we use GPT-4o API to rewrite the original data into a patient-style chief complaint, which is a simple, vague, and non-professional description provided by the patient about their condition without any specific clinical information. This is the only information that LLMs can obtain from patients at the beginning of real-world full-process clinical diagnosis. Besides, we rephrase multiple-choice question in original data into open-ended question, which is closer to real-world clinical diagnosis. The rewritten chief complaint and open-ended question is synthesized into the instruction for the latter tuning.

Thirdly, we give the clinical information to GPT-4o and and design examples and complex prompts (i.e., in-context learning [41]) to instruct GPT-4o to convert the provided information to simulate the step-by-step reasoning process in full-process clinical diagnosis starting with the patient’s chief complaint. In this way, we construct the initial instruction-response pairs to fine-tune our DxDirector-7B. As shown in the “Initial Response” of data transformation stage in Figure 15, each step consists of a question-answer pair in the paradigm of self-questioning and self-answering. The questions are divided into two types: one is inquiries or inference based on objective medical knowledge, such as the causes of a specific disease or determining the possible disease based on the patient’s specific symptoms, and so on. These questions are marked as “<LLM>” and their answers can be finished by LLM itself. The other type of question involves inquiring about the clinical operations for diagnostic test or communication to patients. They are marked as “<Physician>” and their answer must be finished with the help of human physicians. When the reasoning is finished, the “[Final Content]” is generated, it is the summary of the reasoning process, with the number of reasoning steps marked at the corresponding positions. This enhances the credibility and error-correctability of the AI-generated diagnostic process. It is worth noting that GPT-4o cannot effectively perform full-process diagnosis. Therefore, to construct this data, we add the patient’s detailed clinical information to the context to GPT-4o. GPT-4o simulates the full-process diagnosis under the premise of already knowing all

related information, which simplifies the task significantly. This approach enables us to construct a large amount of data that meets the requirements at a relatively low cost.

After transformation, we inject the deep thinking content for each step of “Initial Response”. As shown in deep thinking injection stage in Figure 15, we use o1-preview to generate detailed thinking content for each step of “Initial Response”. This thinking should fully consider the clinical information at the current step and combine it with the ultimate clinical goal to reason about the optimal strategy that should be taken at the current step, which simulates the human “slow thinking” process. Deep thinking makes the logical connection between each step in the whole process of clinical diagnosis closer. These contents often only appear in the minds of human physicians and are not written in electronic medical records. The explicit generation of these contents enables DxDirector-7B to have the “slow thinking” ability like human physicians. We do not generate deep thinking end-to-end during the data transformation stage because we find that doing so will result in deep thinking revealing currently unknown clinical information in advance.

The data instance in final instruction-response pairs for instruction-tuning for full-process clinical diagnosis is the instruction consisting of patient’s chief complaint and clinical question, and the response consisting of multi-step reasoning, deep thinking and final diagnosis.

During data construction, we randomly sample the transformed instruction-response pairs and provide them to human medical experts for evaluation to determine whether this data aligns with real clinical diagnostic scenarios. We collect feedback from the medical experts and continuously refine our prompts to optimize the quality of the data. The detailed prompts in data construction can be found in Supplementary Fig. 11 to 20. Finally, we obtain 10,178 high-quality instruction-response pairs for training.

#### 4.2.2 Training with Decoupled Reasoning and Knowledge

We train DxDirector-7B to perform full-process clinical diagnosis on the constructed dataset above. As shown in instruction-response pair of Figure 15, given the instruction, DxDirector-7B is trained to generate the response consisting of numbered “[Deep Think]” and numbered “[Question] - [Answer]” pairs. “[Deep Think]” and “[Question]” emphasize reasoning capability while “[Answer]” emphasize medical knowledge recalling capability. We propose a decoupled training method based on loss-masking to enable DxDirector-7B to learn these two capabilities separately. It trains the two capabilities alternately in batches. When training reasoning ability, the loss function only computed over the content in “[Deep Think]” and “[Question]”, while the content in “[Answer]” and “[Final Content]” is masked. This allows the LLM to focus on reasoning the questions to be addressed at each step rather than recalling their answers. The cross-entropy loss function  $\mathcal{L}_1$  for this can be computed as:

$$\mathcal{L}_1 = \sum_{R_i \in \mathcal{Q}} -\log \mathcal{M}(R_i|I, R_{1:i-1}; \theta), \quad (2)$$

in which  $\mathcal{M}$  is the distribution of next token prediction of LLM,  $I$  and  $R$  are the instruction and response respectively of instruction-response pair in Figure 15.  $\mathcal{Q}$  is set of tokens in “[Deep Think]” and “[Question]”, and  $R_{1:i-1}$  is the prefix for the token  $R_i$ .

When training knowledge recalling capability, the loss function only includes the content in “[Answer]” and “[Final Content]”, while the content in “[Deep Think]” and “[Question]” is masked. Since some answers need the assistance from human physicians to obtain patient’s clinical information, the input data used to training this ability is accompanied by the extracted patient’s clinical information. The cross-entropy loss function  $\mathcal{L}_2$  for this can be computed as:

$$\mathcal{L}_2 = \sum_{R_i \notin \mathcal{Q}} -\log \mathcal{M}(R_i|I, P, R_{1:i-1}; \theta), \quad (3)$$

in which  $P$  is the patient’s clinical information that used to simulated the assistance from human physicians in training. The details of the hyperparameters in training are provided in the Section 4.5.5.

### 4.3 Step-Level Strategy Preference Optimization

We call the “[Question]” to be solved in each step derived by deep thinking of DxDirector-7B as “strategy”. After instruction-tuning, our DxDirector-7B has initially demonstrated the ability to drive




Figure 16: Pipeline of our data construction for Step-level Strategy Preference Optimization.

full-process clinical diagnoses by generating the strategy step-by-step. However, instruction-tuning with token-level cross-entropy loss function cannot effectively make LLM learn how to make optimal strategy at each step, i.e., generate the most appropriate “[Question]”. The further optimization in this stage enables DxDirector-7B to implicitly compare multiple potential strategies in deep thinking at each step and select the optimal strategy. This ensures that each step in complex clinical reasoning is correct and efficient, so that the diagnosis can be completed accurately while relying on the minimal human physicians’ efforts.

The training method we proposed in this stage is called Step-Level Strategy Preference Optimization, a reinforcement learning algorithm that assigns different rewards to different strategies at the same step and trains DxDirector-7B to generate the strategy with higher reward. To achieve this, first, we construct the training data that consists of multiple strategy labeled with different rewards for each step, and then design the specific method for preference optimization training.

#### 4.3.1 Data Construction

The overview of data construction for this stage can be found in Fig. 16. At step  $t$ , we give instruction  $I$  and reasoning content from steps 1 to  $t-1$ :  $\{(d_1, q_1, a_1), (d_1, q_2, a_2), \dots, (d_{t-1}, q_{t-1}, a_{t-1})\}$  as the input for  $\mathcal{M}_{ft}$ , in which  $d_i$ ,  $q_i$  and  $a_i$  are the deep thinking, question (i.e., strategy) and answer respectively at the  $i$ -th step,  $\mathcal{M}_{ft}$  is the DxDirector-7B after instruction-tuning of the second stage. We change the random seed [18] to make  $\mathcal{M}_{ft}$  output  $k$  different responses at step  $t$ :  $\{(d_t^1, q_t^1, a_t^1), (d_t^2, q_t^2, a_t^2), \dots, (d_t^k, q_t^k, a_t^k)\}$  when faced with this input. In our implementation, we set  $k$  to 3 and more sampling-related hyperparameters can be found in Section 4.5.5. For each response  $(d_t^i, q_t^i, a_t^i)$ , we assign a reward  $r_t^i$  to it based on the correctness of the final answer generated by the reasoning path continued with this response and the degree of reliance on the human physicians. The correct answers are assigned higher rewards. For answers of the same correctness, the strategies that seek more assistance from human physicians will have a lower reward value than other strategies. The reward assigning strategy is as follows:

$$r_t^i = \begin{cases} \frac{10}{\gamma}, & \text{the final answer is correct} \\ 0, & \text{the final answer is incorrect,} \end{cases} \quad (4)$$

in which  $\gamma$  is the number of requesting for assistance from human physicians. We assign a corresponding reward to each response and obtain the set  $S_t = \{(d_t^1, q_t^1, a_t^1, r_t^1), (d_t^2, q_t^2, a_t^2, r_t^2), \dots, (d_t^k, q_t^k, a_t^k, r_t^k)\}$  with rewards at step  $t$ . We generate all

unique ordered pairs over  $\mathcal{S}_t$ , which can be described as:

$$\mathcal{P}_t = \{((d_t^m, q_t^m, a_t^m, r_t^m), (d_t^n, q_t^n, a_t^n, r_t^n)) \mid r_t^m > r_t^n, 1 \leq m \leq k, 1 \leq n \leq k\}. \quad (5)$$

In this way, we can get the data sample for strategy preference optimization training at step  $t$ , it consists of the input  $X_t = I + \{(d_1, q_1, a_1), (d_2, q_2, a_2), \dots, (d_{t-1}, q_{t-1}, a_{t-1})\}$  and a set of paired responses  $\mathcal{P}_t$ . Our strategy preference optimization training method optimizes DxDirector-7B learn to make the better choice in each pair  $((d_t^m, q_t^m, a_t^m, r_t^m), (d_t^n, q_t^n, a_t^n, r_t^n))$  of  $\mathcal{P}_t$ , maximizing the probability of generating the response with the higher reward while minimizing the probability of generating the response with the lower reward. Specific details about this will be introduced in Section 4.3.2. The response with the highest reward in  $\mathcal{P}_t$  will be added to the prefix for data construction in step  $t+1$ . We use this strategy to iterate through each step of 2,000 instruction-response pairs and finally get 23,608 data samples for training, this dataset is denoted as  $\mathcal{D} ((X_t, \mathcal{P}_t) \in \mathcal{D})$ .

### 4.3.2 Step-Level Preference Optimization Training

After data construction, we conduct step-level preference optimization training on  $\mathcal{M}_{ft}$  to make it learn to implicitly compare multiple potential strategies in deep thinking at each step and select the optimal strategy with the principle of ensuring correctness while minimizing the workload of human physicians. The training objective is based on Direct Preference Optimization (DPO) loss function [31]:

$$\mathcal{L}_3(\pi_\theta; \pi_{ref}) = -\mathbb{E}_{(X_t, \mathcal{P}_t) \sim \mathcal{D}} \frac{1}{|\mathcal{P}_t|} \sum_{\substack{((d_t^m, r_t^m), \\ (d_t^n, r_t^n)) \in \mathcal{P}_t}} \left[ \log \sigma \left( \beta \log \frac{\pi_\theta(d_t^m | X_t)}{\pi_{ref}(d_t^m | X_t)} - \beta \log \frac{\pi_\theta(d_t^n | X_t)}{\pi_{ref}(d_t^n | X_t)} \right) \right], \quad (6)$$

in which  $\pi_\theta(b|a)$  is probability of the policy model generating sequence  $b$  given prefix  $a$ ,  $\pi_{ref}(b|a)$  is probability of the reference model generating sequence  $b$  given prefix  $a$ ,  $\beta$  is a hyperparameter usually between 0.1 to 0.5.  $\sigma$  is the sigmoid function. In this training objective, for each sample  $(X_t, \mathcal{P}_t)$  in the training set  $\mathcal{D}$ , we traverse each response pair  $((d_t^m, r_t^m), (d_t^n, r_t^n))$  in  $\mathcal{P}_t$  and align DxDirector-7B’s deep thinking preference for the better strategy through the partial order relationship of rewards between  $(d_t^m, r_t^m)$  and  $(d_t^n, r_t^n)$ , so as to enable DxDirector-7B to implicitly select the optimal strategy to generate among multiple potential strategies. For example,  $X_t$  is the input to  $\mathcal{M}_{ft}$  at the  $t-th$  step,  $r_t^m > r_t^n$ ,  $d_t^m$  is the deep thinking for the strategy with higher reward and  $d_t^n$  is the deep thinking for the strategy with lower reward. To optimize this loss function, DxDirector-7B should learn to maximize the probability of generating  $d_t^m$  and minimize the probability of generating  $d_t^n$ . Since the strategy (“[Question]”) of each step is inferred from the content of deep thinking, optimization for deep thinking is more essential to enable DxDirector-7B to determine the optimal strategy for each step through more reasonable “slow thinking” like human. The details of the training are provided in the Section 4.5.5.

## 4.4 Training to Search Authoritative Medical Literature

After instruction-tuning and preference optimization, as “[Final Content]” shown in Figure 15, our DxDirector-7B can summarize after multi-step reasoning and mark the referenced reasoning step numbers at the corresponding positions. These numbers not only point to the reasoning steps but also indicate references to authoritative medical literature. This innovative design enhances the verifiability and credibility of AI-generated diagnostic content at a fine-grained level. This section introduces our detailed training method for medical literature search model.

### 4.4.1 Training to Search

**Model Architecture.** The base model for search is Gemma-2B [37], a pre-trained language model with stacked 18 transformer layers. We convert Gemma-2B into a vector representation model that can represent the query and each paragraph in medical literature to a dense vector as follows:

Given an input paragraph  $P = \{x_1, x_2, \dots, x_T\}$  with  $T$  tokens, the model outputs hidden states  $\mathbf{H}^l \in \mathbb{R}^{T \times d}$  at each transformer layer  $l \in \{1, 2, \dots, 18\}$ . For text representation, we extract the last token’s hidden state from the final transformer layer:

$$\mathbf{h}_{text} = \mathbf{H}^L[T, :] \in \mathbb{R}^d, \quad (7)$$

in which  $L = 18$  denotes the last transformer layer,  $d = 2048$  is the hidden dimension of Gemma-2B,  $T$  is the sequence length of the input paragraph. This design leverages the autoregressive nature of Gemma-2B, where the final token’s representation naturally aggregates contextual information from all preceding tokens through the transformer’s self-attention mechanism. Given a query seeking medical knowledge, it represents the query and each paragraph in the corpus as vectors. The matching score between a query and a paragraph is determined by calculating the similarity between their vectors such as dot product. The paragraphs are then ranked in descending order based on their matching scores, and the top-k paragraphs are selected as the search results for the given query. To make the search model more accurate in the vector representation of medical text, we train Gemma-2B on large-scale medical data in contrastive learning method, which will be introduced below.

**Data Collection and Process** We collect a large amount of text data from the medical domain to train our model. The training dataset consists of  $11M$  medical articles come from medical textbooks, publications, and case reports. For each article, we use its title as the query and its abstract as the paragraph matched with this query. In this way we construct a large-scale query-paragraph paired data for training the search model.

**Training** We use in-batch contrastive learning to train our model, enabling it to accurately represent text as vectors and rank texts on vector similarity. Specifically, each training batch consists of  $b$  query-paragraph pairs. For the vector representation ( $\mathbf{q}_i$ ) of a query in this batch, its positive sample is the paragraph paired with it ( $\mathbf{p}_i$ ), while its negative samples are the  $b - 1$  paragraphs paired with other queries within the same batch ( $\mathbf{p}_j, j \neq i$ ). For the query, in-batch contrastive learning aims to maximize the its vector similarity between the positive sample while minimizing its vector similarity between negative samples [45, 44]. The loss function to achieve this can be described as:

$$\mathcal{L}_r = -\frac{1}{b} \sum_{i=1}^b \log \frac{e^{\mathbf{q}_i^\top \mathbf{p}_i}}{e^{\mathbf{q}_i^\top \mathbf{p}_i} + \sum_{\substack{j=1 \\ j \neq i}}^b e^{\mathbf{q}_i^\top \mathbf{p}_j}} \quad (8)$$

#### 4.4.2 Fine-grained Medical Literature Search

**Indexing Corpus for Search** We build a large-scale database consisting of 23.9M paragraphs from PubMed, 301.2K paragraphs from StatPearls, 125.8K paragraphs from medical textbooks as the corpus for medical literature search. We use our trained medical search model to represent each paragraph as a vector, and use IndexFlat<sup>7</sup> method based on Faiss<sup>8</sup> to index the vector for Approximate Nearest Neighbor (ANN) [20] search.

**Inference** We use each “[Question]” in multi-step reasoning of DxDirector-7B as the query to our search model. For each query, we use our trained search model to represent it to a vector. Then, we use ANN to search the indexed corpus for the paragraph vector that is closest to the query vector and obtain the paragraph corresponding to this paragraph vector as top-1 ranked paragraph in the search result. We mark this paragraph with corresponding serial number and attach it to the “[Final Content]”. In this way, we provide authoritative medical literature as a reference for each step in complex clinical diagnosis, which enables diagnostic readers to verify the diagnostic content more conveniently and judge the credibility of the diagnostic content in a fine-grained manner.

### 4.5 Details about Experiments

#### 4.5.1 Baselines

The baselines of the experiments can be divided into two categories. One is the open source LLMs specifically optimized for medical scenarios and open source general-purpose LLMs:

1. **Meditron-70B**, it is a medical adapted LLM based on Llama-2-70B, with the continued pretraining on a comprehensively curated medical corpus, including selected PubMed articles, abstracts, and internationally-recognized medical guidelines.

<sup>7</sup><https://github.com/facebookresearch/faiss/blob/main/faiss/IndexFlat.h>

<sup>8</sup><https://github.com/facebookresearch/faiss>

2. **OpenbioLLM-70B**, it is an advanced LLM designed specifically for the biomedical domain based on Llama-3-70B. It achieves state-of-the-art performance on a wide range of biomedical tasks.
3. **Clinical Camel-70B**, it is a medically adapted LLM fine-tuned on the Llama-2 70B architecture using QLoRA. It is tailored for the medical and clinical research, capable of processing and generating relevant content.
4. **Meditron-176B**, it is a generalist medical LLM with 176 billion parameters, pre-trained on a large-scale medical text and real-world clinical records. It shows promising clinical diagnosis performance for cases with complete clinical information.

The other is the current most powerful commercial general-purpose large language models:

1. **GPT-4o**, it is a commercial general-purpose LLM developed by OpenAI. It shows better performance on clinical diagnosis than many medical adapted LLMs such as Meditron-70B, Clinical Camel-70B and Med-Palm-540B.
2. **o1-preview**, it is a commercial general-purpose LLM developed by OpenAI. Compared with GPT-4o, it demonstrates more powerful reasoning capability and recent study has shown that it surpasses human accuracy in making the final clinical diagnosis [4].
3. **o3-mini**, it is a commercial general-purpose LLM developed by OpenAI. Compared with o1-preview, its reasoning ability has been upgraded again, surpassing GPT-4o and o1-preview in many complex tasks.
4. **Gemini-2.0-flash**, it is a commercial general-purpose LLM developed by Google. Its shows better performance than Google's former PaLM 2.
5. **Deepseek-V3-671B**, it is a general-purpose developed by Deepseek. It surpasses GPT-4o in general language understanding and generation capabilities.

#### 4.5.2 Evaluation Metrics

We propose four evaluation metrics in this paper:

1. **Accuracy of Diagnosis.** This is a fully automatic evaluation metric driven by an LLM-based agent, which is used for four publicly available medical datasets including NEJM Clinicopathologic Cases, RareArena, ClinicalBench and USMLE. Specifically, we use instructions to make the final diagnoses generated by LLMs conform to the format of “So the final answer is ...”, so that we can extract the short and clear diagnoses generated by LLMs. For each sample, we compare the extracted diagnosis with the correct answer provided by the datasets to determine whether the generated diagnosis matches the correct answer. This is automatically done based on the gpt-4o-mini agent. We give gpt-4o-mini instructions and examples so that it can make the correct judgment. We statistically analyze the diagnostic accuracy to compare the capabilities of different LLMs.
2. **Number of Clinical Operations.** This metric calculates the average number of operations that human physicians are required to perform when different LLMs complete the full diagnostic process over the whole datasets (the lower the better), which quantifies the workload of human doctors.
3. **Effectiveness of Clinical Operations.** This metric calculates the average of the proportion of operations that are truly useful for making a diagnosis out of all requested operations over the whole datasets. We determine whether an operation is helpful for diagnosis by assessing whether it appears in the case report provided from medical specialists. This metric reflects the accuracy of LLMs in determining which operations are necessary for diagnosis.
4. **Scoring Referred from Medical Specialists.** This metric is applied in real-world diagnosis scenario. Evaluation by medical experts is an important way for us to understand the gap between AI and human physicians in real-world diagnosis. In order to establish an objective evaluation mechanism to prevent bias in human physicians' scoring, we adopt Double-Blinded Adjudication, which makes LLMs and human physicians to give diagnoses to the same patient without seeing each other's content. We introduce a third-party agent to score an LLM based on the degree of match between LLM's diagnosis and human physicians' diagnosis. The third-party agent is based on GPT-4o and Deepseek-V3, and the average of the scores given by them is taken as the actual score. The score range is between 0 and 10.

#### 4.5.3 Ethical Review and Assurance of Clinical Study in Real-World Diagnosis

Our real-world clinical diagnostic scenario is set within an officially certified Grade 3A hospitals in China. The involved patients are inpatients presenting with more complex conditions than typical outpatients. Consequently, LLMs must engage in intricate reasoning to gather comprehensive clinical information effectively. To safeguard patients from potential harm, the evaluation environment is structured as follows: patient behaviors and medical specialist operations during clinical diagnosis are fully recorded using actual inpatient records. Subsequently, two GPT-4o-based agents replicate precisely the recorded behaviors of patients and specialists throughout the diagnostic process. In evaluation, LLMs interact with these agents to drive the full-process diagnosis, initiating solely from the patient's vague chief complaint. Within this controlled environment, LLMs do not directly interact with real patients, and their diagnostic outputs undergo rigorous review by medical specialists, thereby effectively mitigating ethical risks and potential harm. The evaluation is performed on 160 cases across 9 different clinical departments including Gastroenterology, Nephrology, Dermatology, Cardiovascular Medicine, Infectious Diseases, Endocrinology, Pulmonology, General Surgery, and Pain Management.

To ensure objective assessments and mitigate potential biases in human specialists scoring, a double-blind adjudication approach is implemented. In this approach, both human specialists and LLMs independently diagnose the same patient cases without exposure to each other's diagnostic outputs. Additionally, a third-party evaluation agent, utilizing both GPT-4o and Deepseek-V3, assigns scores ranging from 0 to 10 based on the alignment between LLM-generated diagnoses and those provided by medical specialists. The final score is calculated as the average of the scores given by GPT-4o and Deepseek-V3, thus ensuring robust and unbiased comparative assessment. The assessment of whether the diagnoses generated by LLMs could fully replace those made by medical specialists also follows the same pattern by observing the decisions of the third party agent (can or cannot).

All data utilized in this research are exclusively for academic purposes, acquired ethically and legally, and have been reviewed and approved by the relevant institutional ethics committee (IRB00006761-M20250173), ensuring adherence to ethical and legal standards. Data collection rigorously complies with principles of patient privacy protection. No hospital-related information is disclosed, and to further protect patient confidentiality, all personally identifiable information (PII), treatment locations, and other sensitive details are systematically identified and removed by the medical team.

#### 4.5.4 Statistical Information

The error bars reflecting 95% confidence intervals are determined by non-parametric bootstrap procedure with 1,000 samples. As for accuracy, we perform statistical significance tests utilizing the two-side McNemar test between DxDirector-7B and the top-3 baseline, with p-value levels annotated on the bars. As for number of clinical operations, effective of clinical operations and scoring referred from specialists, we use two-side Mann-Whitney U test for statistical significance tests.

#### 4.5.5 Implementations

For continued pre-training and instruction-tuning stage, we use DeepSpeed framework in zero stage 3 to train DxDirector-7B with full parameter fine-tuning on 4 Nvidia A100 80G GPUS. In continued pre-training, we follow Meditron [7] to set  $\beta_1 = 0.9$ ,  $\beta_2 = 0.95$ ,  $\text{eps} = 10^{-5}$  for the AdamW optimizer. The learning rate is  $3 \times 10^{-4}$ . The weight decay is 0.1. The batch size is 1. In instruction-tuning stage, we set  $\beta_1 = 0.9$ ,  $\beta_2 = 0.95$ ,  $\text{eps} = 10^{-5}$  for the AdamW optimizer. The learning rate is  $9.65 \times 10^{-6}$ . The weight decay is 0. The batch size is 1 and training epochs is 3. In step-level strategy preference optimization, first, we input the same prefix to make DxDirector-7B generate multiple different replies by changing random seed at each generation, with sampling parameters as 0.6 temperature, 0.95 top-p and 20 top-k. After data construction, we use the open-source reinforcement learning framework trl<sup>9</sup> to train our model with learning rate as  $5 \times 10^{-7}$ , gradient accumulation steps as 8 and batch size as 1. During the evaluation, we cancel the random sampling setting so that the content generated by LLMs can be fully reproduced.

<sup>9</sup><https://github.com/huggingface/trl>

## 5 Data Availability

After the external review, we promise to provide the datasets for continued pre-training, instruction-tuning and step-level strategy optimization on GitHub<sup>10</sup>. This ensures unrestricted access for anyone to use the data for any purpose, fostering future research and development. We can provide the public available datasets here: RareArena: <https://github.com/zhao-zy15/RareArena>, NEJM Clinicopathologic Cases: <https://www.nejm.org/browse/nejm-article-category/clinical-cases?date=past5Years>, ClinicalBench: <https://github.com/WeixiangYAN/ClinicalLab>, USMLE and MedQA: <https://drive.google.com/file/d/1ImYUSLk9JbgHXOemfyiDiirluZHPeQw/view>.

## 6 Code Availability

To prompt the future research, we promise to release all source codes to train our DxDirector-7B on Github, and the model weights on Huggingface<sup>11</sup> after the external review. This ensures unrestricted access for anyone to use the code and model weights for any purpose, fostering future research and development. Combined with our detailed introduction to the method and the open source datasets, we believe that researchers will find it very easy to reproduce our work.

## References

- [1] Josh Achiam, Steven Adler, Sandhini Agarwal, Lama Ahmad, Ilge Akkaya, Florencia Leoni Aleman, Diogo Almeida, Janko Altenschmidt, Sam Altman, Shyamal Anadkat, et al. Gpt-4 technical report. *arXiv preprint arXiv:2303.08774*, 2023.
- [2] Maggi Banning. A review of clinical decision making: models and current research. *Journal of clinical nursing*, 17(2):187–195, 2008.
- [3] George R Bergus, Gretchen B Chapman, Barcey T Levy, John W Ely, and Robert A Oppliger. Clinical diagnosis and the order of information. *Medical Decision Making*, 18(4):412–417, 1998.
- [4] Peter G Brodeur, Thomas A Buckley, Zahir Kanjee, Ethan Goh, Evelyn Bin Ling, Priyank Jain, Stephanie Cabral, Raja-Elie Abdulnour, Adrian Haimovich, Jason A Freed, et al. Superhuman performance of a large language model on the reasoning tasks of a physician. *arXiv preprint arXiv:2412.10849*, 2024.
- [5] Richard J Chen, Tong Ding, Ming Y Lu, Drew FK Williamson, Guillaume Jaume, Andrew H Song, Bowen Chen, Andrew Zhang, Daniel Shao, Muhammad Shaban, et al. Towards a general-purpose foundation model for computational pathology. *Nature Medicine*, 30(3):850–862, 2024.
- [6] Ying Chen, Guoan Wang, Yuanfeng Ji, Yanjun Li, Jin Ye, Tianbin Li, Bin Zhang, Nana Pei, Rongshan Yu, Yu Qiao, et al. Slidechat: A large vision-language assistant for whole-slide pathology image understanding. *arXiv preprint arXiv:2410.11761*, 2024.
- [7] Zeming Chen, Alejandro Hernández Cano, Angelika Romanou, Antoine Bonnet, Kyle Matoba, Francesco Salvi, Matteo Pagliardini, Simin Fan, Andreas Köpf, Amirkeivan Mohtashami, et al. Meditron-70b: Scaling medical pretraining for large language models. *arXiv preprint arXiv:2311.16079*, 2023.
- [8] Matthew Christensen, Milos Vukadinovic, Neal Yuan, and David Ouyang. Vision–language foundation model for echocardiogram interpretation. *Nature Medicine*, 30(5):1481–1488, 2024.
- [9] Jan Clusmann, Fiona R Kolbinger, Hannah Sophie Muti, Zunamys I Carrero, Jan-Niklas Eckardt, Narmin Ghaffari Laleh, Chiara Maria Lavinia Löffler, Sophie-Caroline Schwarzkopf, Michaela Unger, Gregory P Veldhuizen, et al. The future landscape of large language models in medicine. *Communications medicine*, 3(1):141, 2023.

<sup>10</sup><https://github.com/>

<sup>11</sup><https://huggingface.co/>

- [10] Qingxiu Dong, Lei Li, Damai Dai, Ce Zheng, Jingyuan Ma, Rui Li, Heming Xia, Jingjing Xu, Zhiyong Wu, Baobao Chang, et al. A survey on in-context learning. In *Proceedings of the 2024 Conference on Empirical Methods in Natural Language Processing*, pages 1107–1128, 2024.
- [11] Arthur S Elstein, Lee S Shulman, and Sarah A Sprafka. *Medical problem solving: An analysis of clinical reasoning*. Harvard University Press, 1978.
- [12] Mark L Graber. The incidence of diagnostic error in medicine. *BMJ quality & safety*, 22(Suppl 2):ii21–ii27, 2013.
- [13] Aaron Grattafiori, Abhimanyu Dubey, Abhinav Jauhri, Abhinav Pandey, Abhishek Kadian, Ahmad Al-Dahle, Aiesha Letman, Akhil Mathur, Alan Schelten, Alex Vaughan, et al. The llama 3 herd of models. *arXiv preprint arXiv:2407.21783*, 2024.
- [14] Zhi Huang, Federico Bianchi, Mert Yuksekgonul, Thomas J Montine, and James Zou. A visual–language foundation model for pathology image analysis using medical twitter. *Nature medicine*, 29(9):2307–2316, 2023.
- [15] Aaron Jaech, Adam Kalai, Adam Lerer, Adam Richardson, Ahmed El-Kishky, Aiden Low, Alec Helyar, Aleksander Madry, Alex Beutel, Alex Carney, et al. Openai o1 system card. *arXiv preprint arXiv:2412.16720*, 2024.
- [16] Di Jin, Eileen Pan, Nassim Oufattolle, Wei-Hung Weng, Hanyi Fang, and Peter Szolovits. What disease does this patient have? a large-scale open domain question answering dataset from medical exams. *Applied Sciences*, 11(14):6421, 2021.
- [17] Shreya Johri, Jaehwan Jeong, Benjamin A Tran, Daniel I Schlessinger, Shannon Wongvibulsin, Leandra A Barnes, Hong-Yu Zhou, Zhuo Ran Cai, Eliezer M Van Allen, David Kim, et al. An evaluation framework for clinical use of large language models in patient interaction tasks. *Nature Medicine*, pages 1–10, 2025.
- [18] Klaudia Kaczmarczyk and Karolina Mialkowska. Backtesting comparison of machine learning algorithms with different random seed. *Procedia Computer Science*, 207:1901–1910, 2022.
- [19] Zahir Kanjee, Byron Crowe, and Adam Rodman. Accuracy of a generative artificial intelligence model in a complex diagnostic challenge. *Jama*, 330(1):78–80, 2023.
- [20] Wen Li, Ying Zhang, Yifang Sun, Wei Wang, Mingjie Li, Wenjie Zhang, and Xuemin Lin. Approximate nearest neighbor search on high dimensional data—experiments, analyses, and improvement. *IEEE Transactions on Knowledge and Data Engineering*, 32(8):1475–1488, 2019.
- [21] Aixin Liu, Bei Feng, Bing Xue, Bingxuan Wang, Bochao Wu, Chengda Lu, Chenggang Zhao, Chengqi Deng, Chenyu Zhang, Chong Ruan, et al. Deepseek-v3 technical report. *arXiv preprint arXiv:2412.19437*, 2024.
- [22] Xiaohong Liu, Hao Liu, Guoxing Yang, Zeyu Jiang, Shuguang Cui, Zhaoze Zhang, Huan Wang, Liyuan Tao, Yongchang Sun, Zhu Song, et al. A generalist medical language model for disease diagnosis assistance. *Nature Medicine*, pages 1–11, 2025.
- [23] Ming Y Lu, Bowen Chen, Drew FK Williamson, Richard J Chen, Ivy Liang, Tong Ding, Guillem Jaume, Igor Odintsov, Long Phi Le, Georg Gerber, et al. A visual–language foundation model for computational pathology. *Nature Medicine*, 30(3):863–874, 2024.
- [24] Michael Moor, Qian Huang, Shirley Wu, Michihiro Yasunaga, Yash Dalmia, Jure Leskovec, Cyril Zakka, Eduardo Pontes Reis, and Pranav Rajpurkar. Med-flamingo: a multimodal medical few-shot learner. In *Machine Learning for Health (ML4H)*, pages 353–367. PMLR, 2023.
- [25] Jesutofunmi A Omiye, Haiwen Gui, Shawheen J Rezaei, James Zou, and Roxana Daneshjou. Large language models in medicine: the potentials and pitfalls: a narrative review. *Annals of Internal Medicine*, 177(2):210–220, 2024.
- [26] World Health Organization et al. Global strategy on human resources for health: workforce 2030. In *Global strategy on human resources for health: workforce 2030*. 2016.

- [27] Stephen R Pfahl, Heather Cole-Lewis, Rory Sayres, Darlene Neal, Mercy Asiedu, Awa Dieng, Nenad Tomasev, Qazi Mamunur Rashid, Shekoofeh Azizi, Negar Rostamzadeh, et al. A toolbox for surfacing health equity harms and biases in large language models. *Nature Medicine*, 30(12):3590–3600, 2024.
- [28] Ralph Pinnock and Paul Welch. Learning clinical reasoning. *Journal of Paediatrics and child health*, 50(4):253–257, 2014.
- [29] Pengcheng Qiu, Chaoyi Wu, Shuyu Liu, Weike Zhao, Zhuoxia Chen, Hongfei Gu, Chuanjin Peng, Ya Zhang, Yanfeng Wang, and Weidi Xie. Quantifying the reasoning abilities of llms on real-world clinical cases, 2025.
- [30] Pengcheng Qiu, Chaoyi Wu, Xiaoman Zhang, Weixiong Lin, Haicheng Wang, Ya Zhang, Yanfeng Wang, and Weidi Xie. Towards building multilingual language model for medicine. *Nature Communications*, 15(1):8384, 2024.
- [31] Rafael Rafailov, Archit Sharma, Eric Mitchell, Christopher D Manning, Stefano Ermon, and Chelsea Finn. Direct preference optimization: Your language model is secretly a reward model. *Advances in Neural Information Processing Systems*, 36:53728–53741, 2023.
- [32] Hardeep Singh, Aanand Dinkar Naik, Raghuram Rao, and Laura Ann Petersen. Reducing diagnostic errors through effective communication: harnessing the power of information technology. *Journal of general internal medicine*, 23:489–494, 2008.
- [33] Karan Singhal, Shekoofeh Azizi, Tao Tu, S Sara Mahdavi, Jason Wei, Hyung Won Chung, Nathan Scales, Ajay Tanwani, Heather Cole-Lewis, Stephen Pfahl, et al. Large language models encode clinical knowledge. *Nature*, 620(7972):172–180, 2023.
- [34] Karan Singhal, Tao Tu, Juraj Gottweis, Rory Sayres, Ellery Wulczyn, Mohamed Amin, Le Hou, Kevin Clark, Stephen R Pfahl, Heather Cole-Lewis, et al. Toward expert-level medical question answering with large language models. *Nature Medicine*, pages 1–8, 2025.
- [35] Ryutaro Tanno, David GT Barrett, Andrew Sellergren, Sumedh Ghaisas, Sumanth Dathathri, Abigail See, Johannes Welbl, Charles Lau, Tao Tu, Shekoofeh Azizi, et al. Collaboration between clinicians and vision–language models in radiology report generation. *Nature Medicine*, pages 1–10, 2024.
- [36] Gemini Team, Rohan Anil, Sebastian Borgeaud, Jean-Baptiste Alayrac, Jiahui Yu, Radu Soricut, Johan Schalkwyk, Andrew M Dai, Anja Hauth, Katie Millican, et al. Gemini: a family of highly capable multimodal models. *arXiv preprint arXiv:2312.11805*, 2023.
- [37] Gemma Team, Morgane Riviere, Shreya Pathak, Pier Giuseppe Sessa, Cassidy Hardin, Surya Bhupatiraju, Léonard Hussonot, Thomas Mesnard, Bobak Shahriari, Alexandre Ramé, et al. Gemma 2: Improving open language models at a practical size. *arXiv preprint arXiv:2408.00118*, 2024.
- [38] Augustin Toma, Patrick R Lawler, Jimmy Ba, Rahul G Krishnan, Barry B Rubin, and Bo Wang. Clinical camel: An open expert-level medical language model with dialogue-based knowledge encoding. *arXiv preprint arXiv:2305.12031*, 2023.
- [39] Hugo Touvron, Louis Martin, Kevin Stone, Peter Albert, Amjad Almahairi, Yasmine Babaei, Nikolay Bashlykov, Soumya Batra, Prajjwal Bhargava, Shruti Bhosale, et al. Llama 2: Open foundation and fine-tuned chat models. *arXiv preprint arXiv:2307.09288*, 2023.
- [40] Ines Weinhold and Sebastian Gurtner. Understanding shortages of sufficient health care in rural areas. *Health Policy*, 118(2):201–214, 2014.
- [41] Noam Wies, Yoav Levine, and Amnon Shashua. The learnability of in-context learning. *Advances in Neural Information Processing Systems*, 36:36637–36651, 2023.
- [42] Christian Wirth, Riad Akroud, Gerhard Neumann, and Johannes Fürnkranz. A survey of preference-based reinforcement learning methods. *Journal of Machine Learning Research*, 18(136):1–46, 2017.

- [43] Nicole N Woods, Alan J Neville, Anthony J Levinson, Elizabeth HA Howey, Wieslaw J Oczkowski, and Geoffrey R Norman. The value of basic science in clinical diagnosis. *Academic Medicine*, 81(10):S124–S127, 2006.
- [44] Shicheng Xu, Liang Pang, Huawei Shen, and Xueqi Cheng. A theory for token-level harmonization in retrieval-augmented generation. In *The Thirteenth International Conference on Learning Representations*.
- [45] Shicheng Xu, Liang Pang, Huawei Shen, Xueqi Cheng, and Tat-Seng Chua. Search-in-the-chain: Interactively enhancing large language models with search for knowledge-intensive tasks. In *Proceedings of the ACM Web Conference 2024*, pages 1362–1373, 2024.
- [46] Weixiang Yan, Haitian Liu, Tengxiao Wu, Qian Chen, Wen Wang, Haoyuan Chai, Jiayi Wang, Weishan Zhao, Yixin Zhang, Renjun Zhang, et al. Clinicallab: Aligning agents for multi-departmental clinical diagnostics in the real world. *arXiv preprint arXiv:2406.13890*, 2024.
- [47] Cyril Zakka, Rohan Shad, Akash Chaurasia, Alex R Dalal, Jennifer L Kim, Michael Moor, Robyn Fong, Curran Phillips, Kevin Alexander, Euan Ashley, et al. Almanac—retrieval-augmented language models for clinical medicine. *NEJM AI*, 1(2):A1oa2300068, 2024.
- [48] Shengyu Zhang, Linfeng Dong, Xiaoya Li, Sen Zhang, Xiaofei Sun, Shuhe Wang, Jiwei Li, Runyi Hu, Tianwei Zhang, Fei Wu, et al. Instruction tuning for large language models: A survey. *arXiv preprint arXiv:2308.10792*, 2023.
- [49] Xiaoman Zhang, Chaoyi Wu, Ya Zhang, Weidi Xie, and Yanfeng Wang. Knowledge-enhanced visual-language pre-training on chest radiology images. *Nature Communications*, 14(1):4542, 2023.

## 7 Extended Data

In Fig. 17 to Fig. 22, we show the comparison of the actual output of DxDirector-7B and baseline LLMs for specific cases.

---

**Input:** Chief Complaint: A 34-year-old woman reported experiencing increasing weakness in her legs over the past several years. She mentioned concerns about her sons' health, as they have genetic issues. Additionally, she noted some difficulty with cognitive abilities.  
Question: What disease might this patient have?

---

**Correct Answer:** Duchenne Muscular Dystrophy - Manifesting Carrier

---

**DxDirector-7B:**

<think> <sub-think 1> Let's start by understanding the patient's primary symptoms, particularly those related to her legs and cognitive abilities. </sub-think 1> [Question 1 to <Physician>]: What are the patient's key symptoms related to her legs and cognitive abilities?  
[Answer 1]: The key symptoms related to the patient's legs include progressive weakness in both lower extremities (right hip flexor, hip extensor, knee flexor, knee extensor graded G3%; left hip flexor, hip extensor, knee flexor, knee extensor graded G4-), and elevated serum creatine kinase (CK) levels at 1289 U/L. In terms of cognitive abilities, the patient has an intellectual disability with an IQ of 78.

<sub-think 2> The patient's symptoms of progressive weakness and elevated CK levels suggest a neuromuscular disorder. I need to consider conditions that could cause these symptoms, especially in the context of her family history. </sub-think 2>  
[Question 2 to <LLM>]: What conditions could cause progressive weakness in the legs and elevated serum creatine kinase levels?  
[Answer 2]: Conditions such as muscular dystrophies, particularly Duchenne muscular dystrophy (DMD), could cause progressive muscle weakness and elevated CK levels. Given the patient's family history, it is essential to consider genetic disorders.

<sub-think 3> The patient's family history is crucial here. I need to know if there are any genetic conditions that run in her family, as this could point to a specific diagnosis. </sub-think 3>  
[Question 3 to <Physician>]: What is the patient's family history regarding genetic conditions?  
[Answer 3]: The patient's family history regarding genetic conditions includes two sons with documented exon deletions at exons 43, 44, and 45.

<sub-think 4> The deletions at exons 43, 44, and 45 are well-known mutations associated with a specific genetic disorder. I need to identify which disorder these mutations are most commonly linked to. </sub-think 4>  
[Question 4 to <LLM>]: What genetic disorder is commonly associated with deletions at the DMD gene locations?  
[Answer 4]: Deletions at the DMD gene locations, particularly the deletion of the entire gene (Duchenne muscular dystrophy), are well-known mutations associated with the disease.

<sub-think 5> To confirm the diagnosis, I need to look at the results of the muscle biopsy, which can provide further evidence of a neuromuscular disorder. </sub-think 5>  
[Question 5 to <Physician>]: What findings from the muscle biopsy support a diagnosis?  
[Answer 5]: Findings from the muscle biopsy that support a diagnosis include:  
1. \*\*Muscle weakness predominantly in the lower extremities\*\* with specific grading (G3 to G4+).  
2. \*\*Elevated serum creatine kinase (CK) levels\*\* at 1289 U/L.  
3. \*\*MLPA results showing exon deletions at 43, 44, and 45\*\*, which correlate with the family's history of similar genetic findings.  
4. \*\*Electromyography findings\*\* indicating spontaneous activity and polyphasic potentials, which suggest myopathic changes.

<sub-think 6> Putting it all together, the patient's symptoms, family history, and biopsy findings strongly suggest a genetic neuromuscular disorder. The deletions at the DMD gene locations, along with the elevated CK levels and muscle weakness, point to Duchenne muscular dystrophy as the most likely diagnosis. </sub-think 6>  
[Question 6 to <LLM>]: Given the combination of the patient's symptoms, family history, and biopsy findings, what is the most likely diagnosis?  
[Answer 6]: The patient's progressive weakness, elevated CK levels, and genetic findings (deletions at exons 43, 44, and 45) suggest a diagnosis of Duchenne muscular dystrophy (DMD), a genetic neuromuscular disorder. </think>

<answer> [Final Content]:  
The patient has progressive weakness in her legs, elevated serum creatine kinase levels, and an intellectual disability [1].  
Her family history includes two sons with exon deletions at the DMD gene locations, which is a common genetic mutation associated with a specific disorder [3].  
The muscle biopsy findings, including the deletions at exons 43, 44, and 45, along with the elevated CK levels, support the diagnosis of Duchenne muscular dystrophy [5,6].  
So the final answer is Duchenne muscular dystrophy (DMD).</answer>

Reference:

- [1] Physical examination ...
  - [2] Myopathy -- Evaluation -- 1) Laboratory studies. Blood urea nitrogen and serum creatinine ... (From <https://www.ncbi.nlm.nih.gov/books/NBK562290/>)
  - [3] History Inquiry ...
  - [4] Dystrophinopathies -- Etiology. DMD is 2.2 MB gene with 79 exons, located on the X chromosome. Deletions of exons, particularly in the exonic regions 2 to 20 and 44 to 53, comprise 60% to 70% of pathogenic variants ... (From <https://www.ncbi.nlm.nih.gov/books/NBK534245/>)
  - [5] Findings from the muscle biopsy ....
  - [6] Muscular Dystrophy -- History and Physical. Presentations may also include asymptomatic elevation of serum creatine kinase (CK), exertion intolerance, dilated cardiomyopathy, malignant hyperthermia, quadriceps myopathy, language delay, and in rare cases, Turner syndrome in X chromosome monozygotic females with Duchenne muscular dystrophy ... (From <https://www.ncbi.nlm.nih.gov/books/NBK560582/>)
- 

Figure 17: Our DxDirector-7B on case 1. Blue fonts represent physician input, and others are generated by DxDirector-7B. In reference, the blue fonts record the physician actions, and others are retrieved from authoritative medical literature to provide a verification mechanism for each step in the reasoning. The reference numbers correspond to the steps of thinking-question-answer.

---

**Input:** Chief Complaint: A 34-year-old woman reported experiencing increasing weakness in her legs over the past several years. She mentioned concerns about her sons' health, as they have genetic issues. Additionally, she noted some difficulty with cognitive abilities.  
Question: What disease might this patient have?

**Correct Answer:** Duchenne Muscular Dystrophy - Manifesting Carrier

**GPT-4o:**

Hello! Thank you for coming in today. I want to understand more about the weakness you've been experiencing in your legs. Can you tell me how long you've noticed this weakness and whether it has progressed over time?

The weakness in both legs has been noticed for the past 6 years and it has progressed over that time

I see, thank you for sharing that information. It's important to note the duration and progression of the weakness. Have you experienced any other symptoms alongside the leg weakness, such as numbness, tingling, or changes in sensation in your limbs?

Not mentioned in the provided information

Understood, thank you for clarifying. Based on the information provided about the increasing weakness in the legs over the past several years, concerns about genetic issues in your sons, and difficulties with cognitive abilities, it is possible that you may be experiencing symptoms related to a hereditary disorder. Considering these factors, the likely diagnosis is \*\*myotonic dystrophy\*\*. So the final answer is myotonic dystrophy.

**Deepseek-V3-671B:**

To provide a definite diagnosis, I need to gather more information about the patient's symptoms and medical history. Let's proceed step by step:

1. **\*\*Leg Weakness\*\*:** You mentioned increasing weakness in your legs over the past several years. Could you describe the nature of this weakness? For example, is it constant, does it worsen with activity, or is it accompanied by muscle cramps or pain?
2. **\*\*Cognitive Difficulties\*\*:** You noted some difficulty with cognitive abilities. Could you elaborate on this? Are you experiencing memory loss, trouble concentrating, or difficulty with problem-solving?
3. **\*\*Family History\*\*:** You mentioned concerns about your sons' health and that they have genetic issues. Could you specify what genetic conditions they have? This could be relevant to your diagnosis.
4. **\*\*Other Symptoms\*\*:** Are there any other symptoms you've noticed, such as vision problems, speech difficulties, or changes in coordination?

Please provide this information so I can make a more accurate diagnosis.

1. **\*\*Leg Weakness\*\*:** The weakness in the legs has been progressive over the past 6 years, but the specific nature of the weakness (whether it is constant, worsens with activity, or accompanied by muscle cramps or pain) is not mentioned in the provided information.
2. **\*\*Cognitive Difficulties\*\*:** The patient has an intellectual disability with an IQ of 78, but further details about specific cognitive difficulties such as memory loss, trouble concentrating, or difficulty with problem-solving are not mentioned in the provided information.
3. **\*\*Family History\*\*:** The patient has two sons with documented exon deletions (exon 43, 44, and 45), but specific details about the genetic conditions they may have are not mentioned in the provided information.
4. **\*\*Other Symptoms\*\*:** No other symptoms such as vision problems, speech difficulties, or changes in coordination are mentioned in the provided information.

Based on the information provided, the patient's progressive leg weakness over 6 years, intellectual disability, and family history of exon deletions in her sons strongly suggest a \*\*genetic neuromuscular disorder\*\*. Given the family history of exon deletions (exon 43, 44, and 45), which are commonly associated with \*\*Duchenne Muscular Dystrophy (DMD)\*\* or \*\*Becker Muscular Dystrophy (BMD)\*\*, and the patient's symptoms of progressive leg weakness and cognitive difficulties, the most likely diagnosis is \*\*Becker Muscular Dystrophy (BMD)\*\*. BMD is a milder form of muscular dystrophy that can present with progressive muscle weakness and, in some cases, cognitive impairment. So the final answer is \*\*Becker Muscular Dystrophy (BMD)\*\*

**o3-mini:**

Let's talk a bit more about your condition so I can get a clearer picture. I have a few questions:

- How would you describe the progression of your leg weakness? For example, is it constant or does it seem to worsen at specific times during the day? \n• Do you ever notice any difficulty relaxing your muscles after use (a kind of delayed muscle relaxation or stiffness)?
- Could you describe the cognitive difficulties you mentioned? For example, do you experience memory lapses, trouble concentrating, or something else?
- You mentioned concerns about your sons' health and genetic issues. Can you share more details about what they've been diagnosed with or the specific problems they face?
- Have you experienced any other symptoms, such as issues with your heart (like palpitations), vision changes (like cataracts), or hormonal/endocrine irregularities?

Please provide more details about these points so that we can move toward a definite diagnosis.

The progression of leg weakness is described as progressive over the past 6 years, but it is not specified whether it is constant or worsens at specific times during the day.

- Not mentioned in the provided information.
- The cognitive difficulties described include an intellectual disability with an IQ of 78, but specific issues such as memory lapses or trouble concentrating are not mentioned.
- The two sons have been diagnosed with documented exon deletions (exon 43, 44, and 45), but specific problems they face are not detailed.
- Not mentioned in the provided information.

Based on the details provided—a 34-year-old woman with progressive leg weakness over the past 6 years, mild intellectual impairment (IQ 78), and sons with a documented deletion involving exons 43, 44, and 45—the clinical picture is most consistent with a manifestation of an X-linked dystrophinopathy. In this case, these exon deletions are typical for Becker muscular dystrophy, and although female carriers are often asymptomatic, some manifest symptoms due to skewed X-chromosome inactivation. So the final answer is Becker muscular dystrophy.

---

Figure 18: Baselines on case 1. Blue fonts represent physician input. “Not mentioned” means the required clinical operations are not provided in clinical information of the case reports. The specific prompt enables baselines to perform full-process diagnosis is in Supplementary Fig.21

---

**Input:** Chief Complaint: A 24-year-old male reported experiencing persistent headaches for three weeks, which worsened recently and were accompanied by nausea and vomiting. He also noted some memory issues. Upon seeking help, he felt generally unwell. He had recently emigrated from Mexico and had no significant medical history related to his symptoms.

Question: What disease might this patient have?

---

**Correct Answer:** Neurocysticercosis

**DxDirector-7B:**

<think> <sub-think 1> Let's start by understanding the patient's primary symptoms and their duration. The patient has persistent headaches that worsened recently, along with nausea and vomiting. Memory issues are also mentioned, which could indicate a neurological or infectious process. </sub-think 1> [Question 1 to <Physician>]: What are the patient's primary symptoms and their duration?

[Answer 1]: The patient's primary symptoms included headaches lasting three weeks, severe headache with nausea and vomiting experienced the day before admission, and increasing forgetfulness reported by his mother.

<sub-think 2> Given the patient's recent immigration from Mexico, I need to consider infectious diseases that are prevalent in that region and could cause neurological symptoms. </sub-think 2>

[Question 2 to <LLM>]: What infectious diseases are common in Mexico that could cause neurological symptoms?

[Answer 2]: Infectious diseases such as neurocysticercosis, malaria, and encephalitis are common in Mexico and can present with headaches, nausea, vomiting, and memory issues.

<sub-think 3> To narrow down the diagnosis, I need to know if there are any specific findings on the imaging studies, such as a CT scan, that could point to a particular condition. </sub-think 3>

[Question 3 to <Physician>]: What are the findings on the patient's CT scan?

[Answer 3]: The CT scan findings indicate ventriculomegaly consistent with obstructive hydrocephalus due to an obstruction in the posterior third ventricle, along with an unusual appearance in the third ventricle region. Subsequent MR imaging confirmed migration of a cyst that restored normal cerebrospinal fluid flow.

<sub-think 4> The CT findings of ventriculomegaly and the unusual appearance in the third ventricle suggest a mass effect or obstruction. Given the patient's recent immigration, I need to consider parasitic infections, particularly neurocysticercosis, which is known to cause this type of imaging finding. </sub-think 4>

[Question 4 to <LLM>]: What condition might cause ventriculomegaly and a mass effect in the third ventricle?

[Answer 4]: Neurocysticercosis, caused by the larval stage of the pork tapeworm, can lead to obstructive hydrocephalus and mass effect in the third ventricle, often presenting with headaches, nausea, vomiting, and memory issues.

<sub-think 5> The patient's recent immigration from Mexico is a significant risk factor for neurocysticercosis, as the disease is endemic in many areas of Central and South America. The symptoms and imaging findings strongly support this diagnosis. </sub-think 5>

[Question 5 to <LLM>]: Does the patient have any risk factors for neurocysticercosis?

[Answer 5]: The patient has risk factors for neurocysticercosis due to his emigration from Mexico, where the disease is more prevalent. The pathology findings confirming the presence of the larval stage of the parasite also support this risk.

<sub-think 6> The imaging findings of ventriculomegaly and the unusual appearance in the third ventricle are consistent with the obstruction caused by the larval stage of neurocysticercosis. The patient's recent immigration and symptoms further support this diagnosis. </sub-think 6>

[Question 6 to <LLM>]: What is the significance of the imaging findings in relation to the suspected diagnosis?

[Answer 6]: The imaging findings of ventriculomegaly and the unusual appearance in the third ventricle are consistent with obstruction caused by the larval stage of neurocysticercosis. The pathology findings confirming the presence of the larval stage of the parasite also support this diagnosis. </think>

<answer>[Final Content]: The patient presents with headaches, nausea, vomiting, and memory issues, which are indicative of neurological involvement [1]. His recent immigration from Mexico increases the risk for neurocysticercosis [5].

CT scan findings of ventriculomegaly and unusual appearance in the third ventricle are suggestive of obstruction due to a parasitic infection [3].

The confirmed presence of the larval stage of the pork tapeworm in pathology findings supports the diagnosis of neurocysticercosis [4,6].

So the final answer is Neurocysticercosis. </answer>

Reference:

[1] Symptoms observation ...

[2] Meningitis (Nursing) -- Risk Factors. The most common viral agents of meningitis are non-polio enteroviruses (group b coxsackievirus and echovirus). Other viral causes: mumps, Parechovirus, Herpesviruses (including Epstein Barr virus, Herpes simplex virus ... (From

<https://www.ncbi.nlm.nih.gov/books/NBK568762/>)

[3] Findings of CT ...

[4] InternalMed\_Harrison. Neuroimaging findings suggestive of neurocysticercosis constitute the primary major diagnostic criterion (Fig. 260-1). These findings include cystic lesions with or without enhancement (e.g., ring enhancement), one or more nodular calcifications (which may also have associated enhancement), or focal enhancing lesions. ... (From <https://pmc.ncbi.nlm.nih.gov/articles/PMC4005113/>)

[5] Neurofibroma -- Histopathology. S100 (+) in Schwann cells (approximately 50% of tumor cells) CD34 (+) in spindled fibroblasts with distinct "fingerprint" immunopositivity. ... (From <https://pmc.ncbi.nlm.nih.gov/articles/PMC6108081/>)

[6] InternalMed\_Harrison. Neuroimaging findings suggestive of neurocysticercosis constitute the primary major diagnostic criterion (Fig. 260-1). These findings include cystic lesions with or without enhancement (e.g., ring enhancement), one or more nodular calcifications (which may also have associated enhancement), or focal enhancing lesions. ... (From <https://pmc.ncbi.nlm.nih.gov/articles/PMC4005113/>)

---

Figure 19: Our DxDirector-7B on case 2. Blue fonts represent physician input, and others are generated by DxDirector-7B. In reference, the blue fonts record the physician actions, and others are retrieved from authoritative medical literature to provide a verification mechanism for each step in the reasoning. The reference numbers correspond to the steps of thinking-question-answer.

**Input:** Chief Complaint: A 24-year-old male reported experiencing persistent headaches for three weeks, which worsened recently and were accompanied by nausea and vomiting. He also noted some memory issues. Upon seeking help, he felt generally unwell. He had recently emigrated from Mexico and had no significant medical history related to his symptoms.

Question: What disease might this patient have?

**Correct Answer:** Neurocysticercosis

**GPT-4o**

To narrow down the possible conditions based on the details provided, let me ask you a few questions:

1. When you mention persistent headaches, can you describe the type of pain? Is it more like a dull ache, throbbing, or something else?
2. Have you experienced any changes in your vision, such as blurriness or double vision?
3. Can you tell me more about the memory issues you've faced? Have you noticed any specific patterns or types of information that are particularly difficult to remember?
4. Have you had any recent infections or illnesses before the headaches started?
5. Since you've emigrated from Mexico, do you have any history of travel-related illnesses or diseases common in that region?

Your responses will help me better understand your condition.

1. Not mentioned in the provided information.
2. Not mentioned in the provided information.
3. He experienced increasing forgetfulness.
4. Not mentioned in the provided information.
5. Not mentioned in the provided information.

Thank you for your answers. Given that you are experiencing persistent headaches, nausea, vomiting, memory issues, and you needed urgent treatment after imaging, this could suggest a serious condition related to the brain.

1. Have you had any seizures or unusual movements since the onset of your symptoms?
2. Have you experienced any changes in your sense of smell or taste?
3. Did the headaches change in intensity, or did they start suddenly or gradually?

Your responses will help clarify the situation further.

1. Not mentioned in the provided information.
2. Not mentioned in the provided information.
3. The headaches had a three-week history and were occasionally alleviated by ibuprofen and acetaminophen, but it is not specified whether they changed in intensity or started suddenly or gradually.

Based on the provided information, the key symptoms are persistent headaches, nausea, vomiting, memory issues, and the need for urgent treatment following imaging. These symptoms, particularly in conjunction with the mention of recent emigration from Mexico, raise concern for a serious neurological condition.  
Given the context and the symptoms, one likely diagnosis is a \*\*brain tumor\*\*, which can present with increased intracranial pressure leading to headaches, nausea, vomiting, and cognitive changes. So the final answer is \*\*brain tumor\*\*.

**Deepseek-V3-671B**

To determine the patient's condition, I need to ask a few clarifying questions to narrow down the diagnosis:

1. \*\*Headache Characteristics\*\*: Can you describe the nature of the headaches? Were they throbbing, sharp, or dull? Did they occur at a specific time of day or in a particular location on the head?
2. \*\*Memory Issues\*\*: What kind of memory problems were experienced? Was it difficulty recalling recent events, long-term memories, or both?
3. \*\*Nausea and Vomiting\*\*: Were these symptoms related to eating or did they occur independently? Was there any relief after vomiting?
4. \*\*Imaging Results\*\*: What did the imaging (e.g., MRI or CT scan) reveal? Were there any specific findings such as lesions, swelling, or abnormalities in the brain?
5. \*\*Recent Travel or Exposure\*\*: Since the patient recently emigrated from Mexico, was there any exposure to specific environments, infections, or other risk factors during or after the move?

Please provide this information so I can make a more accurate diagnosis.

1. \*\*Headache Characteristics\*\*: Not mentioned in the provided information.
2. \*\*Memory Issues\*\*: The mother reported increasing forgetfulness
3. \*\*Nausea and Vomiting\*\*: The nausea and vomiting occurred independently, and the patient experienced multiple episodes of vomiting.
4. \*\*Imaging Results\*\*: The initial head CT revealed ventriculomegaly indicative of obstructive hydrocephalus with an obstruction in the posterior third ventricle and an unusual appearance in the third ventricle region. Subsequent MR imaging after EVD placement showed migration of a cyst which restored normal cerebrospinal fluid flow.
5. \*\*Recent Travel or Exposure\*\*: The patient emigrated from Mexico a year prior. There is no specific mention of exposure to environments, infections, or other risk factors during or after the move.

Based on the provided information, the patient's symptoms (persistent headaches, nausea, vomiting, and memory issues) along with the imaging findings (ventriculomegaly, obstructive hydrocephalus, and a cyst in the third ventricle) strongly suggest a specific diagnosis. The migration of the cyst and the restoration of normal cerebrospinal fluid flow after intervention further support this conclusion. So the final answer is \*\*colloid cyst of the third ventricle\*\*.

**o3-mini**

To clarify a few points:

1. You experienced persistent headaches for three weeks that recently worsened, with associated nausea, vomiting, and some memory difficulties.
2. Imaging studies revealed a brain lesion that required urgent intervention.
3. Following surgical (or other urgent) treatment, your symptoms resolved, and you were transferred for rehabilitation.
4. Your background—being a relatively young adult and recently emigrated from Mexico—can be associated with certain infectious risks.

Based on these details, the clinical picture is most consistent with the formation of a localized collection of pus in the brain, which we refer to as a brain abscess. This condition can present with progressively worsening headache, signs of increased intracranial pressure (nausea and vomiting), and cognitive disturbances such as memory issues. Urgent neurosurgical management is often required, followed by a period of rehabilitation, which aligns well with the history provided. So the final answer is brain abscess.

Figure 20: Baselines on case 2. Blue fonts represent physician input. “Not mentioned” means the required clinical operations are not provided in clinical information of the case reports. The specific prompt enables baselines to perform full-process diagnosis is in Supplementary Fig.21

---

**Input:** Chief Complaint: A 57-year-old woman reported a painless bump on her lower lip that has been slowly getting larger over the past three years. She had no history of injury or infection related to the area, and no other significant health issues were noted. After some procedures, the bump was removed, and the healing process went well with no signs of recurrence.  
Question: What disease might this patient have?

**Correct Answer:** Schwannoma

**DxDirector-7B:**

<think> <sub-think 1> Let's analyze the patient's condition. The painless bump on the lower lip that has been growing over three years suggests a possible benign or malignant neoplasm. I need to gather more details about its characteristics. </sub-think 1>

[Question 1 to <Physician>]: What are the characteristics of the bump on the patient's lower lip?

[Answer 1]: The characteristics of the bump on the patient's lower lip include a painless, firm, non-tender swelling measuring 2 cm x 1 cm, which is gradually increasing in size over three years. There is no ulceration, discharge, or skin changes present.

<sub-think 2> The gradual increase in size over three years without any signs of infection or injury is concerning. I need to consider the potential for malignancy, particularly squamous cell carcinoma. </sub-think 2>

[Question 2 to <LLM>]: What type of lesions can present as painless, firm, non-tender swellings, and what are the key histopathological features to consider?

[Answer 2]: Painless, firm, non-tender swellings can be benign or malignant neoplasms, such as fibromas, adenomas, or more concerning, squamous cell carcinoma (SCC). Key histopathological features to consider include the appearance of the nuclei, presence of Verocay bodies, and the overall cellular architecture.

<sub-think 3> The histopathological findings are crucial for determining the nature of the lesion. The presence of Verocay bodies and strong S100 protein positivity suggests a neoplastic process involving squamous cells. </sub-think 3>

[Question 3 to <Physician>]: What are the specific histopathological findings that could indicate a particular type of lesion?

[Answer 3]: The histopathological findings indicating a specific type of lesion in this case are:

1. Predominantly hypercellular (Antoni A) areas with a fascicular pattern of spindled to ovoid nuclei.
2. Presence of Verocay bodies.
3. Strong and diffuse positivity for S100 protein on immunohistochemistry.

<sub-think 4> I need to confirm the typical characteristics of schwannomas to ensure this diagnosis fits the patient's condition. </sub-think 4>

[Question 4 to <LLM>]: What are the characteristics and typical histopathological findings of a schwannoma?

[Answer 4]: Schwannomas are benign neoplasms arising from the schwann cells of the peripheral nerves. They are typically firm, non-tender, and can present as painless bumps or lesions. Histopathologically, they are characterized by a hypercellular pattern with spindle-shaped cells, Verocay bodies, and strong S100 protein positivity.

<sub-think 5> Given the patient's age and the characteristics of the lesion, I can conclude that the most likely diagnosis is a schwannoma, particularly given the painless nature and gradual growth. </sub-think 5>

[Question 5 to <LLM>]: Given the patient's age and symptoms, what is the most likely diagnosis for this painless bump on the lip?

[Answer 5]: Given the patient's age, painless nature, and the gradual growth of the lesion along with the histopathological findings, the most likely diagnosis is a schwannoma (neurilemmoma) rather than any malignant process. </think>

<answer> [Final Content]: The patient has a painless bump on her lower lip that has been increasing in size over three years, with no signs of infection or injury [1]. Histopathological examination shows a hypercellular tumor with a fascicular pattern of spindled nuclei, Verocay bodies, and strong S100 protein positivity, indicating a neoplastic process involving squamous cells [2-3]. These findings align with characteristics typical of schwannomas, which are benign neoplasms [4-5]. So the final answer is a schwannoma (neurilemmoma). <\answer>

Reference:

- [1] Symptoms observation ...
- [2] Skin Cancer -- History and Physical. A thorough skin examination is useful to identify premalignant and malignant skin lesions. It is important to note the location, texture, size, color, shape, borders, and any recent change\ao of suspicious lesions. Premalignant actinic keratoses often present as rough, gritty skin papules on an erythematous base ... (From <https://www.ncbi.nlm.nih.gov/books/NBK557401/>)
- [3] Histopathological findings ...
- [4] InternalMed\_Harrison. Neuroimaging findings suggestive of neurocysticercosis constitute the primary major diagnostic criterion (Fig. 260-1). These findings include cystic lesions with or without enhancement (e.g., ring enhancement), one or more nodular calcifications (which may also have associated enhancement), or focal enhancing lesions. ... (From <https://www.ncbi.nlm.nih.gov/books/NBK539707/>)
- [5] Surgery\_Schwartz. of neural tissue, but rather disordered growth of Schwann cells and nerve axons, often at the site of previous trauma. They can present within surgical scar lines or at the site of previous trauma as flesh-colored papules or nodules and are typically painful. Schwannomas ... (From <https://pubmed.ncbi.nlm.nih.gov/17314203/>)

Figure 21: Our DxDirector-7B on case 3. Blue fonts represent physician input, and others are generated by DxDirector-7B. In reference, the blue fonts record the physician actions, and others are retrieved from authoritative medical literature to provide a verification mechanism for each step in the reasoning. The reference numbers correspond to the steps of thinking-question-answer.

**Input:** Chief Complaint:A 57-year-old woman reported a painless bump on her lower lip that has been slowly getting larger over the past three years. She had no history of injury or infection related to the area, and no other significant health issues were noted. After some procedures, the bump was removed, and the healing process went well with no signs of recurrence.

Question: What disease might this patient have?

Correct Answer: Schwannoma

GPT-4o:

Hello! I understand you're experiencing a painless bump on your lower lip. Let's go through a few questions to gather more information.

1. Can you describe the bump? For instance, is it soft, hard, or fluid-filled?
2. Were there any changes in color of the bump or surrounding skin?
3. Have you noticed any other symptoms associated with the bump, such as swelling, or changes in sensation in the area?
4. Have you had any previous treatments or interventions for the bump before it was removed?
5. Do you have any personal or family history of skin conditions or oral lesions?

This will help me in understanding your situation better.

1. The bump is described as a firm, non-tender swelling.
2. There were no changes in color of the bump or surrounding skin mentioned.
3. The only associated symptom mentioned is that the swelling is painless; no other symptoms such as swelling or changes in sensation are noted.
4. There were no previous treatments or interventions mentioned for the bump before it was removed.
5. There is no personal or family history of skin conditions or oral lesions mentioned in the provided information.

Thank you for providing those details. Based on the characteristics of the bump—firm, non-tender, painless, and slow-growing over three years without any significant changes or associated symptoms—it suggests that it could be a benign condition.  
Given the presentation and the description, it's likely that you had a benign fibrous lesion such as a \*\*fibroma\*\* or possibly a mucous retention cyst (mucocele). However, since the bump was firm and described as not fluid-filled, a \*\*fibroma\*\* is the most likely.  
Since you mentioned that the bump was successfully removed and there have been no signs of recurrence, that further supports that the diagnosis was benign. So the final answer is fibroma.

Deepseek-V3-671B:

Based on the description provided, the patient's condition aligns with a \*\*mucocele\*\*, a common benign lesion of the oral cavity. Mucoceles are typically caused by the accumulation of saliva due to a blocked or damaged minor salivary gland duct. They often present as painless, slow-growing bumps, particularly on the lower lip, and are not associated with a history of injury or infection. The fact that the bump was painless, slowly growing, and located on the lower lip strongly supports this diagnosis. Additionally, the successful removal and lack of recurrence further confirm this.  
So the final answer is \*\*mucocele\*\*.

o3-mini:

Before I reach a final diagnosis, I'd like to ask you a few clarifying questions about the bump on your lower lip:

1. Could you describe its consistency? For example, did it feel soft and compressible or rather firm on palpation?
  2. Did you notice any particular color or discoloration—perhaps a bluish or translucent appearance compared to your normal lip tissue?
  3. Even if you haven't recalled any major injury, have you ever noticed yourself biting or irritating that area (even inadvertently)?
  4. Was the size of the bump always steadily increasing, or did it sometimes fluctuate (for example, enlarging at certain times and then reducing slightly)?
- Your answers to these points will help me determine whether the lesion is most consistent with a mucocele or another type of benign lesion. Please let me know.
1. Not mentioned in the provided information
  2. Not mentioned in the provided information
  3. Not mentioned in the provided information
  4. The size of the bump was described as gradually increasing over three years, with no mention of fluctuations.

Based on the provided case details and considering the lesion's characteristics—a painless, gradually enlarging bump on the lower lip that was successfully removed with no recurrence—the findings are most consistent with a mucocele. So the final answer is mucocele.

Figure 22: Baselines on case 3. Blue fonts represent physician input. “Not mentioned” means the required clinical operations are not provided in clinical information of the case reports. The specific prompt enables baselines to perform full-process diagnosis is in Supplementary Fig.21